EP1749203A2 - Systemes de detection de cellules electroniques en temps reel et applications en matiere de profilage de cytotoxicite et dosages de composes - Google Patents

Systemes de detection de cellules electroniques en temps reel et applications en matiere de profilage de cytotoxicite et dosages de composes

Info

Publication number
EP1749203A2
EP1749203A2 EP05722991A EP05722991A EP1749203A2 EP 1749203 A2 EP1749203 A2 EP 1749203A2 EP 05722991 A EP05722991 A EP 05722991A EP 05722991 A EP05722991 A EP 05722991A EP 1749203 A2 EP1749203 A2 EP 1749203A2
Authority
EP
European Patent Office
Prior art keywords
cell
cells
test compound
impedance
well
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05722991A
Other languages
German (de)
English (en)
Other versions
EP1749203A4 (fr
Inventor
Xiao Xu
Yama Abbassi
Xiaobo Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/987,732 external-priority patent/US7192752B2/en
Application filed by Individual filed Critical Individual
Priority to EP11193882.5A priority Critical patent/EP2450698B1/fr
Priority to EP13171137.6A priority patent/EP2639576B1/fr
Publication of EP1749203A2 publication Critical patent/EP1749203A2/fr
Publication of EP1749203A4 publication Critical patent/EP1749203A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/4833—Physical analysis of biological material of solid biological material, e.g. tissue samples, cell cultures
    • G01N33/4836—Physical analysis of biological material of solid biological material, e.g. tissue samples, cell cultures using multielectrode arrays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
    • C12M25/06—Plates; Walls; Drawers; Multilayer plates
    • C12M25/08—Plates; Walls; Drawers; Multilayer plates electrically charged
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
    • C12M41/30—Means for regulation, monitoring, measurement or control, e.g. flow regulation of concentration
    • C12M41/36—Means for regulation, monitoring, measurement or control, e.g. flow regulation of concentration of biomass, e.g. colony counters or by turbidity measurements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/02—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance
    • G01N27/021—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance before and after chemical transformation of the material

Definitions

  • This invention relates to the field of cell-based assays.
  • the invention provides impedance-based devices, apparatuses and systems for analyzing cells and for conducting cell-based assays.
  • Bioelectronics is a progressing interdisciplinary research field that involves the integration of biomatereials with electronic devices. Bioelectronic methods have been used for analyzing cells and assaying biological molecules and cells. In one type of application, cells are cultured on microelectrodes and cell-electrode impedance is measured and determined to monitor cellular changes.
  • a device for detecting cells and/or molecules on an electrode surface is disclosed.
  • the device detects cells and/or molecules through measurement of impedance changes resulting from the attachment or binding of cells and/or molecules to the electrode surfaces.
  • a number of embodiments ofthe device is disclosed, together with the apparatuses, system for using such devices to perform certain cell based assays.
  • time dependent IC50's are derived and different time dependent patterns for IC50's are observed (e.g., see Hassan SB, Jonsson E, Larsson R and Karlsson MO in J. Pharmacology and Experimental Therapeutics, 2001, Vol. 299, No. 3, pp 1140-1147; Levasseur LM, Slocum HK, Rustum YM and Greco WR, in Cancer Research, 1998, vol. 58, pp 5749-5761.). Typically, these studies used end-point single-measurement assays.
  • the present invention is directed to a device for monitoring cell- substrate impedance, which device comprises: a) a nonconducting substrate; b) two or more electrode arrays fabricated on the substrate, where each ofthe two or more electrode arrays comprises two electrode structures; and c) at least two connection pads, each of which is located on an edge ofthe substrate.
  • Each electrode array ofthe device has an approximately uniform electrode resistance distribution across the entire array.
  • the substrate ofthe device has a surface suitable for cell attachment or growth; where cell attachment or growth on said substrate can result in a detectable change in impedance between or among the electrode structures within each electrode array.
  • each electrode array on the substrate of a device ofthe present invention is associated with a fluid-impermeable container.
  • the present invention is directed to a cell-substrate impedance measurement system comprising: a) at least one multiple-well device monitoring cell- substrate impedance, in which at least two ofthe multiple wells each comprise an electrode array at the bottom ofthe well; b) an impedance analyzer; c) a device station capable of engaging the one or more multiple-well devices and capable of selecting and electrically connecting electrode arrays within any ofthe multiple wells in to the impedance analyzer; and d) a software program to control the device station and perform data acquisition and data analysis on impedance values measured by the impedance analyzer.
  • each electrode array ofthe multiple-well device is individually addressed.
  • the present invention provides a method for monitoring cell- substrate impedance using a device ofthe present invention.
  • the method includes: providing a multiple array device ofthe present invention; connecting said multiple array device to an impedance analyzer; depositing cells on at least one ofthe two or more arrays ofthe device; and monitoring cell-substrate impedance on one or more arrays of the device.
  • the present invention provides methods for calculating a Cell Change Index for quantifying and comparing cell-substrate impedance.
  • the present invention provides methods for calculating resistance of electrical traces connecting an array of a cell-substrate monitoring device with a connection pad. Such calculations of electrical trace resistance can be used for calculating Cell Index.
  • the present invention provides a method for monitoring cell- substrate impedance using a cell-substrate impedance measurement system ofthe present invention. The method includes: providing a cell-substrate impedance measurement system ofthe present invention, adding cells to at least one well ofthe multiple- well device that comprises an electrode array, and monitoring cell-substrate impedance from one or more ofthe wells that comprise cells. Impedance can be monitored at regular or irregular time intervals. In preferred embodiments, cell-substrate impedance is monitored in at least two wells of a multiple- well device.
  • the present invention provides a method for performing real-time cell-based assays investigating the effects of one or more compound on cells, comprising: providing an above described cell-substrate impedance measurement system; introducing cells into at least one well ofthe system that comprises an electrode array; adding one or more compounds to one or more ofthe wells containing cells; and monitoring cell-substrate impedance over the electrode array ofthe one or more wells before and after adding the one or more compounds.
  • cell-substrate impedance is monitored at regular or irregular time intervals after adding one or more compounds to the one or more ofthe wells containing cells.
  • the time dependent impedance change can provide information about time dependent cell status before addition ofthe compound and about time dependent cell status under the interaction ofthe compound. This information can be used to determine the effect of a compound on the cells.
  • the present invention provides a method for performing real-time cytotoxicity assays of at least one compound, comprising: providing an above described cell-substrate impedance measurement system; introducing cells into one or more wells ofthe system that comprise an electrode array; adding one or more compounds to the one or more wells containing cells; and monitoring cell-substrate impedance ofthe one or more wells before and after adding the one or more compounds, wherein the time dependent impedance change provides information about time dependent cytotoxicity ofthe compound or compounds.
  • cell-substrate impedance is monitored at regular or irregular time intervals after adding one or more compounds to the one or more ofthe wells containing cells.
  • the time dependent impedance change can provide information about any potential cytotoxic effects ofthe compound.
  • the present invention provides a method for analyzing and comparing time-dependent effects of a first compound and a second compound on a cell type, comprising: a) performing a real-time assay on a cell type with the first compound using the method described above; b) performing a real-time assay on said cell type with the second compound using the method described above; and c) comparing the time- dependent responses ofthe first compound and the second compound.
  • time-dependent cellular responses are determined for a first compound at multiple dose concentrations. In another embodiment, time-dependent responses are determined for a second compound at multiple dose concentrations, yet another embodiment, time-dependent cellular responses are determined for both a first compound and a second compound at multiple dose concentrations.
  • the present invention provides methods for cytotoxicity profiling for a compound on multiple cell types, comprising: a) performing real-time cytotoxicity assays on different cell types with the compound using the method described above, and b) analyzing real-time cytotoxic responses of different cell types to the compound to provide a cytotoxicity profile ofthe compound.
  • the above methods are applied to perform cytotoxicity profiling of multiple compounds on multiple cell types.
  • Figure 1 shows schematic drawings of one design of a cell-substrate impedance measurement device ofthe present invention.
  • A) depicts the substrate having 16 electrode arrays (or 16 electrode structure units) that are arranged in a 2-row by 8-column configuration on a substrate.
  • B) depicts a single electrode array of a device.
  • C) shows a schematic drawing of an electrode array, illustrating the requirement of approximately uniform distribution of electrode resistance across the array.
  • Figure 2 shows real-time monitoring of proliferation of H460 cells seeded at different initial cell seeding numbers on a cell substrate impedance monitoring system ofthe presnet invention.
  • the cell proliferation was continuously recorded every 15 minutes for over 125 hours.
  • the cell growth curves in the log scale show exponential cell growth or cells in the stationary phase.
  • Figure 3 shows real time monitoring of cell attachment and spreading of NIH3T3 cells using a cell-substrate imepdnace monitoring system ofthe presnet invention.
  • the cells were seeded onto devices coated with either poly- L-lysine or fibronectin.
  • the cell attachment and cell spreading processes on the different coating surfaces were monitored every 3 minutes for over 3 hours in real time.
  • Figure 4 shows real-time monitoring of morphological changes in Cos-7 cells uisng a cell-substrate impedance monitoring system ofthe presnet invention.
  • the cells were serum starved for 8 hours and stimulated with or without 50 ng/niL EGF. Changes in cell morphology were monitored at 3 min intervals for 2 hours and then 1 hour interval for 14 hours.
  • the initial jump in the signal in EGF-treated cells is due to membrane ruffling and actin dynamics in response to EGF.
  • the arrow indicates the point of EGF stimulation.
  • Figure 5 shows time-dependent cell index for H460 cells treated by anticancer drug paclitaxel.
  • Different wells of cultured H460 cells were treated at their exponential growth phase with different concentrations of Paclitaxel.
  • the dynamic response ofthe cells to different doses of paclitaxel was monitored in real time every 15 minutes for 50 hours after treatment using a cell-substrate impedance monitoring system ofthe presnet invention.
  • paclitaxel concentration between 67 nM and 500 nM
  • H460 cells exhibited a gradual decrease in cell index initially after the compound addition. However, the cell index reached a minimum at a time dependent on the compound concentration between about 15 hours and 20 hours after compound addition. After that point, the cell index exhibited a gradual increase in cell index.
  • the cell index for compound concentration of 33 nM exhibited a near-constant value for time up to about 15 hours after compound addition. After 15 hours following the compound addition, the cell index exhibited a gradual increase in cell index.
  • Figure 6 shows time-dependent cell index for H460 cells treated by anticancer drug AC 101103. Different wells of cultured H460 cells were treated at their exponential growth phase with different concentrations of AC101103. The dynamic response ofthe cells to different doses of AC101103 was monitored in real time every 30 minutes for about 20 hours on a cell substrate impedance monitoring system ofthe presnet invention. The time-dependent cell index in Figure 6 is significantly different from those shown in Figure 5. For compound concentrations at 3.125 ug/ml, 6.25 ug/ml and 12.5 ug/ml, the cell index exhibited a near-constant value for about 5 hrs, about 15 hrs and > 20 hrs respectively.
  • the cell index started to increase after about 5 hrs and about 15 hrs following compound addition.
  • the compound concentration of 25 ug/ml there was a gradual, yet slow decrease in the cell index after compound addition.
  • the compound concentration of 50 ug/ml there was an about 10 hr time period over which the cell index remained near-constant, and after that, the cell index decreased steadily.
  • Figure 7 shows dynamic drug response curves of A549 cells treated with doxorubicin.
  • 10,000 A549 cells were seeded in each well of a 16 X device.
  • the cell attachment and cell growth were monitored on the cell-substrate impedance monitoring system ofthe present invention in real time before treatment.
  • doxorubicin at different concentration was added to the cells.
  • Same volume of a solvent used for dissolve the drug was served as vehicle control.
  • the time, and drug dose dependent cell response to doxorubicin was recorded in real time.
  • Figure 8 shows titration of NEH3T3 cells on the devices ofthe present invention.
  • the indicated cell number of cells were seeded into microtiter devices fabricated with electronic sensor arrays shown in Figure IB.
  • the electronic sensor arrays were- precoated with fibronectin. Two hours after seeding, the cell index number was determined using a cell-substrate imepdnace monitoring system ofthe present invention.
  • Figure 9 A and B shows the responses of various cell types (listed in Table 1) to doxorubicin treatment as monitored using a cell-substrate imepdnace monitoring system ofthe presnet invention.
  • the indicated cell lines were seeded onto microtiter devices fabricated with electronic sensor arrays shown in Figure IB.
  • the cellular responses were continuously monitored at 15 or 30 or 60 minutes time interval before and after treatment with doxorubicin.
  • Figure 10A and B shows the responses of various cell types (listed in Table 1) to olomoucine treatment as monitored using a cell-substrate imepdnace monitoring system ( ofthe presnet invention.
  • the indicated cell lines were seeded onto microtiter devices fabricated with electronic sensor arrays shown in Figure IB.
  • the cellular responses were continuously monitored at 15 or 30 or 60 minutes time interval before and after treatment with olomoucine.
  • Figure IIA and 11B show the responses of various cell types (listed in Table 1) to paclitaxel treatment as momtored using a cell-substrate imepdnace monitoring system of the presnet invention.
  • the indicated cell lines were seeded onto microtiter devices fabricated with electronic sensor arrays shown in Figure IB.
  • the cellular responses were continuously momtored at 15 or 30 or 60 minutes time interval before and after treatment with paclitaxel.
  • Figure 12 A shows the response of MV522 cells to doxorubicin treatment as monitored using a cell-substrate imepdnace monitoring system ofthe presnet invention.
  • MV522 cells were seeded onto microtiter devices fabricated with electronic sensor arrays shown in Figure IB and were treated with either DMSO or doxorubicin at the indicated time and concentration.
  • Figure 12B shows the characterization ofthe cell biological effect of doxorubicin treatment on MV522 cells.
  • the cells were either processed for cell cycle analysis using FACS or treated with CFDA and Cy3-Annexin V to assess cell viability.
  • the cells were fixed and stained with phalloidin to examine cell morphology. For viability and morphology, the cells were visualized and photographed using a fluorescence microscope equipped with CCD camera.
  • Figure 13 A shows the response of A549 cells to olomoucine treatment as monitored using a cell-substrate imepdnace monitoring system ofthe presnet invention.
  • A549 cells were seeded onto microtiter devices fabricated with electronic sensor arrays shown in Figure IB and were treated with either DMSO or olomoucine at the indicated time and concentration.
  • Figure 13B shows the characterization ofthe cell biological effect of olomoucine treatment on MN522 cells.
  • the cells were either processed for cell cycle analysis using FACS or treated with CFDA and Cy3-Annexin N to assess cell viability.
  • the cells were fixed and stained with phalloidin to examine cell morphology. For viability and morphology, the cells were visualized and photographed using a fluorescence microscope equipped with CCD camera.
  • Figure 14A shows the response of A549 cells to paclitaxel treatment as monitored using a cell-substrate imepdnace monitoring system ofthe presnet invention.
  • A549 cells were seeded onto microtiter devices fabricated with electronic sensor arrays shown in Figure IB and were treated with either DMSO or paclitaxel at the indicated time and concentration.
  • Figure 14B shows the characterization ofthe cell biological effect of paclitaxel n treatment on A549 cells.
  • the cells were either processed for cell cycle analysis using FACS or treated with CFDA and Cy3-Annexin N to assess cell viability.
  • the cells were fixed and stained with phalloidin to examine cell morphology. For viability and morphology, the cells were visualized and photographed using a fluorescence microscope equipped with CCD camera.
  • Figure 15 The time dependent IC values for each compound ( 15A: Doxorubicin; 15B: Paclitaxel; 15C: Olomoucine; 15D: Tamoxifan) for the indicated cell lines as estimated at 5 hr intervals from the cell index curves obtained using a cell-substrate imepdnace monitoring system ofthe presnet invention .
  • Figure 16A shows the cell index curves of HT29 cells before and after treatment with various compounds. Also shown is an theoretical exponential increase of cell index with time (labeled as “Log-growth, model”) and cells treated with DMSO vehicle control (labeled as “Control, HT29”).
  • Figure 16B shows the derived cell change index (CCI) from the cell index curves shown in Figure 16 A. Also shown is the "black- white shading codes" used for different responses based on the convention shown in Figure 16C.
  • CCI derived cell change index
  • Figure 16C shows the color-coding scheme used for representing the CCI curves. If the DT is the doubling time for the cells undergoing exponential growth in the cell culture media used, then CCI having different values relative to 0.7/DT indicates the different cell change status. If CCI » 0.7/DT, cell index increases faster than that expected for an exponential growth (or log growth) ofthe cells (such region n the CCI curve is represented as ssfe Rectangle). If CCI is about 0.7/DT, cell index increases in the same rate as that expected for an exponential growth ofthe cells (such region in the CCI curve
  • FIG 17 shows the cell response profile of each cell line tested against the indicated chemotherapeutic agents.
  • CCI time-dependent cell change index
  • DOX doxorubicin
  • 5-F 5-Fluorouracil
  • COL Colcemid
  • TAXOL paclitaxel
  • NIN vinblastin
  • OLOM Olomoucine
  • ROS Roscovitine
  • STAU Staurosporine
  • TAMO Tamoxifan
  • RIFA Rifampicin
  • ACEA-1 an ACEA test compound.
  • FIG. 1 Dynamic monitoring of cell proliferation.
  • HI 080 fibrosarcoma cells, H460 lung cancer cells, HepG2 hepatosarcoma cancer cells and NIH3T3 mouse fibroblast cell lines were seeded at a density of 2500 and 10,000 cells per well of ACEA 96x e-Plate device.
  • the adhesion, spreading and proliferation ofthe cells were dynamically monitored every 30 minutes using a cell-substrate imepdnace monitoring system ofthe presnet invention.
  • Figure 19 Correlation between cell-substrate impedance measurement (as shown here, Cell Index) and number of cells seeded and comparison of Cell Index with MTT.
  • FIG. 20 Dynamic monitoring of drug interaction with target cells using a cell- substrate imepdnace monitoring system ofthe presnet invention.
  • A A549 cells were seeded in a device of present invention at a density of 10,000 cells per well and the cells were contmuously monitored up to 24 hours at which point paclitaxel was added at the indicated final concentrations.
  • B Annexin V staining of A549 cells treated with DMSO or 12.5 nM paclitaxel for 20 hours. The cells were observed with fluorescence microscope and images were captured with an attached digital camera.
  • FIG. 21 Dynamic monitoring of cell cycle arrest using a cell-substrate imepdnace monitoring system ofthe presnet invention.
  • A549 cells were seeded in a device of present invention at 10,000 cells per well and continuously monitored using the RT-CES. The cells were treated with either (A) DMSO or 100 ⁇ M Olomoucine (B) A549 cells growing on tissue culture dishes for 20 hours were treated with DMSO or 100 ⁇ M Olomoucine. Cell cycle analysis was performed by flow cytometry.
  • FIG. 22 Dynamic monitoring of cytotoxic compounds with target cells using a cell- substrate imepdnace monitoring system ofthe presnet invention.
  • A549 cells were seeded in a device ofthe present inventoon and continuously monitored using the RT-CES system. The cells were treated with the indicated final concentrations of (A) staurosporine, (B) vinblastine and (C) 5-flourouracil.
  • A) staurosporine (B) vinblastine and (C) 5-flourouracil.
  • membrane is a sheet of material.
  • biocompatible membrane means a membrane that does not have deleterious effects on cells, including the viability, attachment, spreading, motility, growth, or cell division.
  • a surface ofthe vessel is suitable for cell attachment" when a significant percentage ofthe cells are adhering to the surface ofthe vessel within twelve hours.
  • at least 50% o the cells are adhering to the surface ofthe vessel within twelve hours.
  • a surface that is suitable for cell attachment has surface properties so that at least 70% ofthe cells are adhering to the surface within twelve hours of plating (i.e., adding cells to the vessel).
  • the surface properties of a surface that is suitable for cell attachment results in at least 90% ofthe cells adhering to the surface within twelve hours of plating. Most preferably, the surface properties of a surface that is suitable for cell attachment results in at least 90% ofthe cells adhering to the surface within eight, six, four, two hours of plating.
  • the surface may need to chemically-treated (e.g. treatment with an acid and/or with a base), and/or physically treated (e.g. treatment with plasma), and or biochemically treated (e.g.
  • a biocompatible surface such as a membrane
  • a biocompatible surface preferably is suitable for the attachment of cells ofthe type that are to be used in an assay that uses the biocompatible surface (e.g., membrane), and most preferably, allows the attachment of at least 90% ofthe cells that contact the biocompatible surface during the assay.
  • a “biomolecular coating” is a coating on a surface that comprises a molecule that is a naturally occurring biomolecule or biochemical, or a biochemical derived from or based on one or more naturally occurring biomolecules or biochemicals.
  • a biomolecular coating can comprise an extracellular matrix component (e.g., fibronectin, collagens), or a derivative thereof, or can comprise a biochemical such as polylysine or polyornithine, which are polymeric molecules based on the naturally occurring biochemicals lysine and ornithine.
  • Polymeric molecules based on naturally occurring biochemicals such as amino acids can use isomers or enantiomers ofthe naturally- occuring biochemicals.
  • extracellular matrix component is a molecule that occurs in the extracellular matrix of an animal. It can be a component of an extracellular matrix from any species and from any tissue type. Nonlimiting examples of extracellular matrix components include laminins, collagens fibronectins, other glycoproteins, peptides, glycosaminoglycans, proteoglycans, etc. Extracellular matrix components can also include growth factors.
  • Electrode is a structure having a high electrical conductivity, that is, an electrical conductivity much higher than the electrical conductivity ofthe surrounding materials.
  • an “electrode structure” refers to a single electrode, particularly one with a complex structure (as, for example, a spiral electrode structure), or a collection of at least two electrode elements that are electrically connected together. All the electrode elements within an “electrode structure” are electrically connected.
  • electrode element refers to a single structural feature of an electrode structure, such as, for example, a fmgerlike projection of an interdigitated electrode structure.
  • an “electrode array” or “electrode structure unit” is two or more electrode structures that are constructed to have dimensions and spacing such that they can, when connected to a signal source, operate as a unit to generate an electrical field in the region of spaces around the electrode structures.
  • Preferred electrode structure units of the present invention can measure impedance changes due to cell attachment to an electrode surface.
  • Non-limiting examples of electrode structure units are interdigitated electrode structure units and concentric electrode structure units.
  • Electrode bus is a portion of an electrode that connects individual electrode elements or substructures.
  • An electrode bus provides a common conduction path from individual electrode elements or individual electrode substructures to another electrical connection.
  • an electrode bus can contact each electrode element of an electrode structure and provide an electrical connection path to electrical traces that lead to a connection pad.
  • Electrode traces or “electrically conductive traces” or “electrical traces”, are electrically conductive paths that extend from electrodes or electrode elements or electrode structures toward one end or boundary of a device or apparatus for connecting the electrodes or electrode elements or electrode structures to an impedance analyzer.
  • the end or boundary of a device may correspond to the comiection pads on the device or apparatus.
  • connection pad is an area on an apparatus or a device ofthe present invention which is electrically connected to at least one electrode or all electrode elements within at least one electrode structure on an apparatus or a device and which can be operatively connected to external electrical circuits (e.g., an impedance measurement circuit or a signal source).
  • external electrical circuits e.g., an impedance measurement circuit or a signal source.
  • the electrical connection between a connection pad and an impedance measurement circuit or a signal source can be direct or indirect, through any appropriate electrical conduction means such as leads or wires.
  • Such electrical conduction means may also go through electrode or electrical conduction paths located on other regions of the apparatus or device.
  • Interdigitated means having projections coming one direction that interlace with projections coming from a different direction in the manner ofthe fingers of folded hands (with the caveat that interdigitated electrode elements preferably do not contact one another).
  • a "high probability of contacting an electrode element” means that, if a cell is randomly positioned within the sensor area of a device or apparatus ofthe present invention, the probability of a cell (or particle) contacting on an electrode element, calculated from the average diameter of a cell used on or in a device or apparatus ofthe present invention, the sizes ofthe electrode elements, and the size ofthe gaps between electrode elements, is greater than about 50%, more preferably greater than about 60%, yet more preferably greater than about 70%, and even more preferably greater than about 80%, greater than about 90%, or greater than about 95%.
  • At least two electrodes fabricated on said substrate means that the at least two electrodes are fabricated or made or produced on the substrate.
  • the at least two electrodes can be on the same side ofthe substrate or on the different side ofthe substrate.
  • the substrate may have multiple layers, the at least two electrodes can be either on the same or on the different layers ofthe substrate.
  • At least two electrodes fabricated to a same side of said substrate means that the at least two electrodes are fabricated on the same side ofthe substrate.
  • At least two electrodes fabricated to a same plane of said substrate means that, if the nonconducting substrate has multiple layers, the at least two electrodes are fabricated to the same layer ofthe substrate.
  • said . . . electrodes [or electrode structures] have substantially the same surface area means that the surface areas ofthe electrodes referred to are not substantially different from each other, so that the impedance change due to cell attachment or growth on any one ofthe electrodes (or electrode structures) referred to will contribute to the overall detectable change in impedance to a same or similar degree as the impedance change due to cell attachment or growth on any other ofthe electrodes (or electrode structures) referred to. In other words, where electrodes (or electrode structures) have substantially the same surface area, any one ofthe electrodes can contribute to overall change in impedance upon cell attachment or growth on the electrode.
  • the ratio of surface area between the largest electrode and the smallest electrode that have “substantially the same surface area” is less than 10.
  • the ratio of surface area between the largest electrode and the smallest electrode of an electrode array is less than 5, 4, 3, 2, 1.5, 1.2 or 1.1. More preferably, the at least two electrodes of an electrode structure have nearly identical or identical surface area.
  • said device has a surface suitable for cell attachment or growth
  • the electrode and/or non-electrode area ofthe apparatus has appropriate physical, chemical or biological properties such that cells of interest can viably attach on the surface and new cells can continue to attach, while the cell culture grows, on the surface ofthe apparatus.
  • the device, or the surface thereof contain substances necessary for cell viability or growth. These necessary substances, e.g., nutrients or growth factors, can be supplied in a medium.
  • a suspension of viable, unimpaired, epithelial or endothelial cells is added to the "surface suitable for cell attachment" when at least 50% ofthe cells are adhering to the surface within twelve hours.
  • a surface that is suitable for cell attachment has surface properties so that at least 70% ofthe cells are adhering to the surface within twelve hours of plating (i.e., adding cells to the chamber or well that comprises the said device). Even more preferably, the surface properties of a surface that is suitable for cell attachment results in at least 90% ofthe cells adhering to the surface within twelve hours of plating. Most preferably, the surface properties of a surface that is suitable for cell attachment results in at least 90% ofthe cells adhering to the surface within eight, six, four, two hours of plating.
  • detecttable change in impedance between or among said electrodes means that the impedance between or among said electrodes (or electrode structures) would have a significant change that can be detected by an impedance analyzer or impedance measurement circuit when molecule binding reaction occurs on the electrode surfaces.
  • the impedance change refers to the difference in impedance values when molecule binding reaction occurs on the electrode surface ofthe apparatus and when no molecular reaction occurs on the electrode surface.
  • the impedance change refers to the difference in impedance values when cells are attached to the electrode surface and when cells are not attached to the electrode surface, or when the number, type, activity, adhesiveness, or morphology of cells attached to the electrode- comprising surface ofthe apparatus changes.
  • the change in impedance is larger than 0.1% to be detectable.
  • the detectable change in impedance is larger than 1%, 2%, 5%, or 8%. More preferably, the detectable change in impedance is larger than 10%.
  • Impedance between or among electrodes is typically a function ofthe frequency ofthe applied electric field for measurement. "Detectable change in impedance between or among said electrodes" does not require the impedance change at all frequencies being detectable.
  • Detectable change in impedance between or among said electrodes only requires a detectable change in impedance at any single frequency (or multiple frequencies), i addition, impedance has two components, resistance and reactance (reactance can be divided into two categories, capacitive reactance and inductive reactance). "Detectable change in impedance between or among said electrodes” requires only that either one of resistance and reactance has a detectable change at any single frequency or multiple frequencies. In the present application, impedance is the electrical or electronic impedance.
  • the method for the measurement of such impedance is achieved by, (1) applying a voltage between or among said electrodes at a given frequency (or multiple frequencies, or having specific voltage waveform) and monitoring the electrical current through said electrodes at the frequency (or multiple frequencies, or having specific waveform), dividing the voltage, amplitude value by the current amplitude value to derive the impedance value; (2) applying an electric current of a single frequency component (or multiple frequencies or having specific current wave form) through said electrodes and monitoring the voltage resulted between or among said electrodes at the frequency (or multiple frequencies, or having specific waveform), dividing the voltage amplitude value by the current amplitude value to derive the impedance value; (3) other methods that can measure or determine electric impedance.
  • said at least two electrodes have substantially different surface area
  • the surface areas of any electrodes are not similar to each other so that the impedance change due to cell attachment or growth on the larger electrode will not contribute to the overall detectable impedance to a same or similar degree as the impedance change due to cell attachment or growth on the smaller electrodes.
  • any impedance change due to cell attachment or growth on the larger electrode is significantly smaller than the impedance change due to cell attachment or growth on the smaller electrode.
  • the ratio of surface area between the largest electrode and the smallest electrode is more than 10.
  • the ratio of surface area between the largest electrode and the smallest electrode is more than 20, 30, 40, 50 or 100.
  • multiple pairs of electrodes or electrode structures spatially arranged according to wells of a multi-well microplate means that the multiple pairs of electrodes or electrode structures of a device or apparatus are spatially arranged to match the spatial configuration of wells of amulti-well microplate so that, when desirable, the device can be inserted into, joined with, or attached to a multiwell plate (for example, a bottomless multiwell plate) such that multiple wells ofthe multi-well microplate will comprise electrodes or electrode structures.
  • arranged in a row-column configuration means that, in terms of electric connection, the position of an electrode, an electrode array or a switching circuit is identified by both a row position number and a column position number.
  • each well contains substantially same number . . . of cells
  • the lowest number of cells in a well is at least 50% ofthe highest number of cells in a well.
  • the lowest number of cells in a well is at least 60%, 70%, 80%, 90%, 95% or 99% ofthe highest number of cells in a well. More preferably, each well contains an identical number of cells.
  • each well contains . . .same type of cells means that, for the intended purpose, each well contains same type of cells; it is not necessary that each well contains exactly identical type of cells.
  • each well contains same type of mammalian cells, e.g., human cells, or different mammalian cells, e.g., human cells as well as other non-human mammalian cells such as mice, goat or monkey cells, etc.
  • each well contains . . . serially different concentration of a test compound
  • each well contains a test compound with a serially diluted concentrations, e.g., an one-tenth serially diluted concentrations of 1 M, 0.1 M, 0.01 M, etc.
  • dose-response curve means the dependent relationship of response of cells on the dose concentration of a test compound.
  • the response of cells can be measured by many different parameters. For example, a test compoimd is suspected to have cytotoxicity and cause cell death. Then the response of cells can be measured by percentage of non- viable (or viable) cells after the cells are treated by the test compound. Plotting this percentage of non- viable (or viable) cells as a function ofthe does concentration ofthe test compound constructs a dose response curve. In the present application, the percentage of non- iable (or viable) cells can be expressed in terms of measured impedance values, or in terms of cell index derived from impedance measurement, or in terms of cell change indexes.
  • cell index can be shown to have a linear correlation or positive correlation with the number of viable cells in a well from which cell index was derived from the impedance measurement.
  • dose-response curve the dose-response curve
  • cell index not only correlate with the number of viable cells in the wells but also relate to the cell morphology and cell attachment.
  • plotting cell index versus doss concentration provides information not only about number of cells but also about their physiological status (e.g. cell morphology and cell adhesion).
  • the electrodes have, along the length ofthe microchannel, a length that is substantially less than the largest single-dimension of a particle to be analyzed” means that the electrodes have, along the length ofthe microchannel, a length that is at least less than 90% ofthe largest single-dimension of a particle to be analyzed.
  • the electrodes have, along the length ofthe microchannel, a length that is at least less than 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5% ofthe largest single- dimension of a particle to be analyzed.
  • an aperture having a pore size that equals to or is slightly larger than size of said particle means that aperture has a pore size that at least equals to the particle size but less than 300% ofthe particle size.
  • both pore size and particle size are measured in terms of single dimension value.
  • microelectrode strip or electrode strip means that a nonconducting substrate strip on which electrodes or electrode structure units are fabricated or incorporated.
  • the non-limiting examples ofthe non-conducting substrate strips include polymer membrane, glass, plastic sheets, ceramics, insulator-on-semiconductor, fiber glass (like those for manufacturing printed-circuits-board).
  • Electrode structure units having different geometries can be fabricated or made on the substrate strip by any suitable microfabrication, micromachining, or other methods.
  • Non-limiting examples of electrode geometries include interdigitated electrodes, circle-on-line electrodes, diamond- on-line electrodes, castellated electrodes, or sinusoidal electrodes.
  • Characteristic dimensions of these electrode geometries may vary from as small as less than 5 micron, or less than 10 micron, to as large as over 200 micron, over 500 micron, over 1 mm.
  • the characteristic dimensions ofthe electrode geometries refer to the smallest width ofthe electrode elements, or smallest gaps between the adjacent electrode elements, or size of a repeating feature on the electrode geometries.
  • the microelectrode strip can be of any geometry for the present invention.
  • One exemplary geometry for the microelectrode strips is rectangular shape - having the width ofthe strip between less than 50 micron to over 10 mm, and having the length ofthe strip between less than 60 micron to over 15 mm.
  • An exemplary geometry ofthe microelectrode strips may have a geometry having a width of 200 micron and a length of 20 mm.
  • a single microelectrode strip may have two electrodes serving as a measurement unit, or multiple such two-electrodes serving as multiple measurement units, or a single electrode structure unit as a measurement unit, or multiple electrode structure units serving as multiple electrode structure units, hi one exemplary embodiment, when multiple electrode structure units are fabricated on a single microelectrode strip, these electrode structure units are positioned along the length direction ofthe strip.
  • the electrode structure units may be of squared-shape, or rectangular-shape, or circle shapes. Each of electrode structure units may occupy size from less than 50 micron by 50 micron, to larger than 2 mm x 2mm.
  • sample refers to anything which may contain a moiety to be isolated, manipulated, measured, quantified, detected or analyzed using apparatuses, microplates or methods in the present application.
  • the sample may be a biological sample, such as a biological fluid or a biological tissue.
  • biological fluids include suspension of cells in a medium such as cell culture medium, urine, blood, plasma, serum, saliva, semen, stool, sputum, cerebral spinal fluid, tears, mucus, amniotic fluid or the like.
  • Bio tissues are aggregates of cells, usually of a particular kind together with their intercellular substance that fonn one ofthe structural materials of a human, animal, plant, bacterial, fungal or viral structure, including connective, epithelium, muscle and nerve tissues.
  • biological tissues also include organs, tumors, lymph nodes, arteries and individual cell(s).
  • the biological samples may further include cell suspensions, solutions containing biological molecules (e.g. proteins, enzymes, nucleic acids, carbohydrates, chemical molecules binding to biological molecules) .
  • a “liquid (fluid) sample” refers to a sample that naturally exists as a liquid or fluid, e.g., a biological fluid.
  • a “liquid sample” also refers to a sample that naturally exists in a non-liquid status, e.g., solid or gas, but is prepared as a liquid, fluid, solution or suspension containing the solid or gas sample material.
  • a liquid sample can encompass a liquid, fluid, solution or suspension containing a biological tissue.
  • test compound is any compound whose activity or direct or indirect effect or effects on cells is investigated in any assay.
  • a test compound can be any compound, including, but not limited to, a small molecule, a large molecule, a molecular complex, an organic molecule, an inorganic molecule, a biomolecule such as but not limited to a lipid, a steroid, a carbohydrate, a fatty acid, an amino acid, a peptide, a protein, a nucleic acid, or any combination of these.
  • a test compound can be a synthetic compound, a naturally occurring compound, a derivative of a naturally-occurring compound, etc. The structure of a test compound can be known or unknown.
  • a "known compound” is a compound for which at least one activity is known.
  • a known compound preferably is a compound for which one or more direct or indirect effects on cells is known.
  • the structure of a known compound is known, but this need not be the case.
  • the mechanism of action of a known compound on cells is known, for example, the effect or effects of a known compound on cells can be, as nonlimiting examples, effects on cell viability, cell adhesion, apoptosis, cell differentiation, cell proliferation, cell morphology, cell cycle, IgE-mediated cell activation or stimulation, receptor-ligand binding, cell number, cell quality, cell cycling, etc.
  • impedance value is the impedance measured for electrodes in a well with or without cell present. Impedance is generally a function ofthe frequency, i.e., impedance values depend on frequencies at which the measurement was conducted. For the present application, impedance value refers to impedance measured at either single frequency or multiple frequencies. Furthermore, impedance has two components, one resistance component and one reactance component. Impedance value in the present application refers to resistance component, or reactance component, or both resistance and reactance component. Thus, when “impedance value” was measured or monitored, we are referring to that, resistance, or reactance, or both resistance and reactance were measured or monitored. In many embodiments ofthe methods ofthe present application, impedance values also refer to parameter values that are derived from raw, measured impedance data. For example, cell index, or normalized cell index, or delta cell index could be used to represent impedance values.
  • a "Cell Index” or “CI” is a parameter that can derived from measured impedance values and that can be used to reflect the change in impedance values. There are a number of methods to derive or calculate Cell Index.
  • a “Normalized Cell Index” at a given time point is calculated by dividing the Cell Index at the time point by the Cell Index at a reference time point. Thus, the Normalized Cell Index is 1 at the reference time point.
  • a “delta cell index” at a given time point is calculated by subtracting the cell index at a standard time point from the cell index at the given time point. Thus, the delta cell index is the absolute change in the cell index from an initial time (the standard time point) to the measurement time.
  • a "Cell Change Index” or "CCI” is a parameter derived from Cell Index and "CCI" at a time point is equal to the 1 st order derive ofthe Cell Index with respect to time, divided by the Cell Index at the time point.
  • CCI is calculated as dCI(t)
  • the present invention includes devices for measuring cell-substrate impedance that comprise a nonconducting substrate; two or more electrode arrays fabricated on the substrate, where each ofthe two or more electrode arrays comprises two electrode structures; and at least two connection pads, each of which is located on an edge ofthe substrate.
  • Each electrode array ofthe device has approximately uniform electrode resistance across the entire array.
  • the substrate ofthe device has a surface suitable for cell attachment or growth; where cell attachment or growth on said substrate can result in a detectable change in impedance between or among the electrode structures within each electrode array.
  • An electrode array is two or more electrode structures that are constructed to have dimensions and spacing such that they can, when connected to a signal source, operate as a unit to generate an electrical field in the region of spaces around the electrode structures.
  • An electrode structure refers to a single electrode, particularly one with a complex structure. (For example, an electrode structure can comprise two or more electrode elements that are electrically connected together.)
  • an electrode array comprises two electrode structures, each of wliich comprises multiple electrode elements, or substructures, hi preferred embodiments ofthe present invention, the electrode structures of each ofthe two or more electrode arrays of a device have substantially the same surface area.
  • each ofthe two or more electrode arrays of a device comprise two electrode structures, and each electrode structure comprises multiple electrode elements.
  • Each ofthe two electrode structures of an electrode array is connected to a separate connection pad that is located at the edge ofthe substrate.
  • each of the two or more electrode arrays ofthe device for each ofthe two or more electrode arrays ofthe device, the first ofthe two electrode structures is connected to one ofthe two or more connection pads, and the second ofthe two electrode structures is connected to another ofthe two or more connection pads.
  • each array of a device is individually addressed, meaning that the electrical traces and connection pads ofthe arrays are configured such that an array can be connected to an impedance analyzer in such a way that a measuring voltage can be applied across a single array at a given time by using switches (such as electronic switches).
  • switches such as electronic switches.
  • Each electrode array ofthe device has an approximately uniform electrode resistance distribution across the entire array.
  • uniform resistance distribution across the array is meant that when a measurement voltage is applied across the electrode structures ofthe array, the electrode resistance at any given location ofthe array is approximately equal to the electrode resistance at any other location on the array.
  • the electrode resistance at a first location on an array ofthe device and the electrode resistance at a second location on the same array does not differ by more than 30%. More preferably, the electrode resistance at a first location on an array ofthe device and the electrode resistance at a second location on the same array does not differ by more than 15%. Even more preferably, the electrode resistance at a first location on an array ofthe device and a second location on the same array does not differ by more than 5%. More preferably yet, the electrode resistance at a first location on an array ofthe device and a second location on the same array does not differ by more than 2%.
  • the electrode elements For a device ofthe present invention, preferred arrangements for the electrode elements, gaps between the electrodes and electrode buses in a given elecfrode array are used to allow all cells, no matter where they land and attach to the electrode surfaces, to contribute similarly to the total impedance change measured for the electrode array.
  • the field strength is related to the potential difference between the nearest point on a first electrode structure ofthe array and the nearest point on a second electrode structure ofthe array. It is therefore desirable to have similar electric potential drops across the electrode elements and across the electrode buses of a given array.
  • the electrode resistance at a location of interest is equal to the sum ofthe electrode resistance between the nearest point on a first electrode structure (that is the point on the first electrode structure nearest the location of interest) and a first connection pad connected to the first electrode structure and the electrode resistance between the nearest point on a second electrode structure (that is the point on the first electrode structure nearest the location of interest) and a second connection pad connected to the second electrode structure.
  • Devices ofthe present invention are designed such that the arrays ofthe device have an approximately uniform distribution across the whole array.
  • Electrodes and electrode buses of particular spacing and dimensions (lengths, widths, thicknesses and geometrical shapes) such that the resistance at any single location on the array is approximately equal to the resistance at any single other location on the array.
  • the electrode elements (or electrode structures) of a given array will have even spacing and be of similar thicknesses and widths
  • the elecfrode buses of a given array will be of similar thicknesses and widths
  • the electrode traces leading from a given array to a connection pad will be of closely similar thicknesses and widths.
  • an array is designed such that the lengths and geometrical shapes of electrode elements or structures, the lengths and geometrical shapes of electrode traces, and the lengths and geometrical shapes of buses allow for approximately uniform electrode resistance distribution across the array.
  • electrode structures comprise multiple electrode elements, and each electrode element connects directly to an electrode bus. Elecfrode elements of a first electrode structure connect to a first elecfrode bus, and electrode elements of a second electrode structure connect to a second electrode bus. hi these embodiments, each ofthe two electrode buses connects to a separate connection pad via an electrical trace. Although the resistances ofthe traces contribute to the resistance at a location on the array, for any two locations on the array the trace connections from the first bus to a first connection pad and from the second bus to a second connection pad are identical. Thus, in these preferred embodiments trace resistances do not need to be taken into account in designing the geometry ofthe array to provide for uniform resistances across the array.
  • a device for monitoring cell- substrate impedance has two or more electrode arrays that share a connection pad.
  • one ofthe elecfrode structures of at least one ofthe electrode arrays ofthe device is connected to a connection pad that also connects to an electrode structure of at least one other ofthe elecfrode arrays ofthe device.
  • each ofthe two or more arrays has a first elecfrode structure connected to a connection pad that connects with an electrode structure of at least one other electrode array, and each ofthe two or more arrays has a second electrode structure that connects to a connection pad that does not connect with any other electrode structures or arrays ofthe device.
  • each ofthe electrode structures of an array is connected to an electrode bus that is connected to one ofthe two or more connection pads ofthe device via an electrically conductive trace.
  • each ofthe two electrode structures is connected to a single bus, such that each array connects to two buses, one for each electrode structures. In this arrangement, each ofthe two buses connects to a separate connection pad ofthe substrate.
  • the electrically conductive traces that connect a bus with a connection can be fabricated of any electrically conductive material.
  • the traces can be localized to the surface ofthe substrate, and can be optionally covered with an insulating layer. Alternatively the traces can be disposed in a second plane ofthe substrate. Description of arrangements and design of electrically conductive traces on impedance measurement devices can be found in parent U.S. Patent Application 10/705,447, herein incorporated by reference for all disclosure on fabrication and design of electrically conductive trace on substrates.
  • Appropriate electronic connection means such as metal clips engaged onto the connection pads on the substrate and connected printed-circuit-boards can be used for leading the electronic connections from the connection pads on the devices to external electronic circuitry (e.g. an impedance analyzer).
  • the nonconducting substrate is planar, and is flat or approximately flat.
  • Exemplary substrates can comprise many materials, including, but not limited to, silicon dioxide on silicon, silicon-on-insulator (SOI) wafer, glass (e.g., quartz glass, lead glass or borosilicate glass), sapphire, ceramics, polymer, fiber glass, plastics, e.g., polyimide (e.g. Kapton, polyimide film supplied by DuPont), polystyrene, polycarbonate, polyvinyl chloride, polyester, polypropylene and urea resin.
  • the substrate and the surface ofthe substrate are not going to interfere with molecular binding reactions that will occur at the substrate surface.
  • any surface ofthe nonconducting substrate that can be exposed to cells during the use of a device ofthe present invention is preferably biocompatible.
  • Substrate materials that are not biocompatible can be made biocompatible by coating with another material, such as polymer or biomolecular coating.
  • All or a portion ofthe surface of a substrate can be chemically treated, including but not limited to, modifying the surface such as by addition of functional groups, or addition of charged or hydrophobic groups.
  • electrode arrays used for impedance measurement that apply to the devices ofthe present invention are described in parent U.S. Patent Application No. 10/705,447, herein incorporated by reference for all disclosure relating to electrode arrays (or structural units), electrode structures, electrode materials, electrode dimensions, and methods of manufacturing electrodes on substrates.
  • Preferred electrode arrays for devices ofthe present invention include arrays comprising two elecfrode structures, such as, for example, spiral elecfrode arrays and interdigitated arrays.
  • electrode arrays are fabricated on a substrate, in which the arrays comprises two elecfrode structures, each of which comprises multiple circle-on-line electrode elements, in which the electrode elements of one structure alternate with the electrode elements ofthe opposite electrode structure.
  • the electrode elements (or electrode structures) of an array ofthe present device ofthe present invention are of approximately equal widths.
  • the electrode elements (or electrode structures) of an array ofthe present device ofthe present invention are greater than 30 microns in width, more preferably from about 50 to about 300 microns in width, and more preferably yet about 90 microns in width.
  • the electrode elements (or electrode structures) of an array ofthe present device ofthe present invention are approximately evenly spaced.
  • the gap between electrode elements (or electrode structures) of an array ofthe present device ofthe present invention is less than 50 microns in width, more preferably from about 5 to about 30 microns in width, and more preferably yet about 20 microns in width.
  • a device ofthe present invention can include one or more fluid-impermeable receptacles which serve as fluid containers. Such receptacles may be reversibly or irreversibly attached to or formed within the substrate or portions thereof (such as, for example, wells formed as in a microtiter plate).
  • the device ofthe present invention includes microelectrode strips reversibly or irreversibly attached to plastic housings that have openings that correspond to electrode structure units located on the microelectrode strips.
  • Suitable fluid container materials comprise plastics, glass, or plastic coated materials such as ceramics, glass, metal, etc. Descriptions and disclosure of devices that comprise fluid containers can be found in parent U.S. Patent Application No. 10/705,447, herein incorporated by reference for all disclosure of fluid containers and fluid container structures that can engage a substrate comprising electrodes for impedance measurements, including their dimensions, design, composition, and methods of manufacture.
  • each electrode array on the substrate of a device ofthe present invention is associated with a fluid-impermeable container or receptacle, such as, for example, a well.
  • the device ofthe present invention is assembled to a bottomless, multiwell plastic plate or strip with a fluid tight seal.
  • the device is assembled such that a single array of the substrate is at the bottom of a receptacle or well.
  • each array of a device is associated with a well of a multiwell plate, h some preferred embodiments, a multiwell device for cell-substrate impedance measurement has "non-array" wells that are attached to the subsfrate but not associated with arrays. Such wells can optionally be used for performing non-impedance based assays, or for viewing cells microscopically.
  • a device ofthe present invention preferably has between 2 and 1,536 wells, more preferably between 4 and 384 wells, and even more preferably, between 16 and 96 wells, all or less than all or which are associated with elecfrode arrays.
  • commercial tissue culture plates can be adapted to fit a device ofthe present invention.
  • Bottomless plates may also be custom-made to preferred dimensions.
  • well diameters are from about 1 millimeter to about 20 millimeters, more preferably from about 2 millimeters to about 8 millimeters at the bottom ofthe well (the end disposed on the substrate).
  • the wells can have a uniform diameter or can taper toward the bottom so that the diameter ofthe container at the end in contact with the substrate is smaller than the diameter ofthe opposing end.
  • the present invention also includes methods of using a device ofthe present invention that comprises fluid containers situated over electrode arrays to measure cell- substrate impedance. Such methods include: providing a device ofthe present invention that comprises fluid containers situated over elecfrode arrays, attaching an impedance analyzer to a device ofthe present invention, adding cells to one or more fluid containers ofthe device, and measuring impedance over one or more arrays ofthe device. Methods of performing cell assays using impedance measurement devices can be found in parent U.S. Patent Application No. 10/987,732 and U.S. Patent Application 10/705,447, both herein incorporated by reference for all disclosure of methods of using impedance measurement devices, as well as in Sections D and E ofthe present application.
  • the present invention is directed to a cell-substrate impedance measurement system
  • a cell-substrate impedance measurement system comprising a) at least one multiple-well cell-substrate impedance measuring device, in which at least two ofthe multiple wells comprise an electrode array at the bottom ofthe well; b) an impedance analyzer electronically connected to the multiple-well cell-substrate impedance measuring device; c) a device station capable of engaging the one or more multiple- well devices and comprising electronic circuitry capable of selecting and connecting electrode arrays within any ofthe multiple wells to the impedance analyzer; and d) a software program connected to the device station and impedance analyzer to control the device station and perform data acquisition and data analysis from the impedance analyzer.
  • the impedance analyzer engages connection pads of one or more multi-well devices to measure impedance, h one embodiment ofthe above system, the impedance analyzer is capable of measuring impedance between 0.1 ohm and 10 ohm in frequency range of 1Hz to 1 MHz.
  • the impedance analyzer is preferably capable of measuring both resistance and reactance (capacitive reactance and inductive reactance) components ofthe impedance.
  • the impedance analyzer is capable of measuring impedance between 0.1 ohm and 10 3 ohm in frequency range of 100 Hz to 100 kHz.
  • a cell-substrate measurement system can be used to efficiently and simultaneously perform multiple assays by using circuitry ofthe device station to digitally switch from recording from measuring impedance over an array in one well to measuring impedance over an array in another well, h one embodiment ofthe above system, the system under software control is capable of completing an impedance measurement for an individual well at a single frequency within less than ten seconds. In another embodiment, the averaged time used by the system to complete an impedance measurement for an individual well at a single frequency is less than one second.
  • a multiple- well cell-substrate impedance measuring device in a system ofthe present invention can be any multiple-well cell-substrate impedance measuring device in which at least two ofthe multiple wells comprise an electrode array at the bottom ofthe well, and in which at least two ofthe multiple wells comprise an electrode array are individually addressed.
  • the multi-well device takes the form of a specialized microtiter plate which has microelectronic sensor arrays integrated into the bottom ofthe wells.
  • a device used in a system ofthe present invention when connected to an impedance analyzer, can measure differences in impedance values that relate to cell behavior.
  • a cell-substrate impedance measuring device used in a system of the present invention can measure differences in impedance values when cells are attached to the electrode array and when cells are not attached to the electrode array, or can detect differences in impedance values when the number, type, activity, adhesiveness, or morphology of cells attached to the electrode-comprising surface ofthe apparatus changes.
  • Preferred devices that can be part of a cell-substrate impedance monitoring system can be those described in parent U.S. Patent Application No. 10/705,447, and in U.S. Patent Application No.
  • cell-substrate impedance monitoring devices that comprise electrode arrays, including disclosure of their design, composition, and manufacture.
  • Preferred devices that can be part of a cell-substrate impedance monitoring system can also be those described in the present application.
  • a multi-well device of a system ofthe present invention comprises between 4 and 1,536 wells, some or all of which can comprise electrode arrays.
  • a device station can comprise one or more platforms or one or more slots for positioning one or more multiwell devices.
  • the one or more platforms or one or more slots can comprise sockets, pins or other devices for electrically connecting the device to the device station.
  • the device station preferably can be positioned in a tissue culture incubator during cell impedance measurement assays. It can be electrically connected to an impedance analyzer and computer that are preferably located outside the tissue culture incubator.
  • the device station comprises electronic circuitry that can connect to an impedance monitoring device and an impedance analyzer and electronic switches that can switch on and off connections to each ofthe two or more electrode arrays ofthe multiwell devices used in the system.
  • the switches ofthe device station are controlled by a software program.
  • the software program directs the device station to connect arrays of the device to an impedance analyzer and monitor impedance from one or more ofthe elecfrode arrays.
  • the impedance analyzer can monitor impedance at one frequency or at more than one frequency.
  • impedance monitoring is performed at more than one time point for a given assay, and preferably, impedance is monitored at at least three time points.
  • the device station can connect individual arrays of a device to an impedance analyzer to monitor one, some, or all ofthe arrays of a device for a measurement time point.
  • the switches ofthe device station allow the selected individual arrays to be monitored in rapid succession for each desired monitoring time point.
  • Each monitoring time point is in fact a narrow time frame (for example from less than one second to minutes) of measurement in the assay during which impedance monitoring is performed.
  • the device station software is programmable to direct impedance monitoring of any ofthe wells ofthe device that comprise arrays at chosen time intervals.
  • the software ofthe impedance monitoring system can also store and display data. Data can be displayed on a screen, as printed data, or both. Preferably the software can allow entry and display of experimental parameters, such as descriptive information including cells types, compound concentrations, time intervals monitored, etc. Preferably, the software can also analyze impedance data. In preferred embodiments, the software can calculate a cell index (CI) for one or more time points for one or more wells ofthe multiwell device. In some preferred embodiments, the software can calculate a cell change index (CCI) from impedance measurements of one or more wells ofthe multiwell device. The software can preferably generate plots of impedance data and impedance values, such as but not limited to CI or CCI, with respect to time.
  • CI cell index
  • CCI cell change index
  • the software may perform other analysis as well, such as calculate cell number from CI, generate dose-response curves based on impedance data, calculate IC values based on impedance values, and calculate kinetic parameters of cell growth or behavior based on impedance values and impedance value curves.
  • the software ofthe impedance monitoring system can also store and display analyses ofthe data, such as calculated impedance values and kinetic parameters derived therefrom, Data can be displayed on a screen, as printed data, or both.
  • cell index in the present application is the same as "cell number index” in PCT Application No. PCT/US03/22557,entitled “IMPEDANCE BASED DEVICES AND METHODS FOR USE IN ASSAYS", filed on My 18, 2003 and in United States patent application No.
  • the present invention provides several methods of calculating cell index numbers for cells attached to two or more essentially identical arrays of a cell-substrate impedance device, where the cells are monitored for impedance changes.
  • the methods calculate cell index number with better accuracy than previous methods of calculating cell index for cells on two or more arrays of a cell- substrate monitoring device.
  • methods of calculating a cell index rely on novel methods for calculating the resistances of electrical traces leading to two or more essentially identical arrays.
  • the present invention therefore also includes methods of calculating resistances of electrical traces leading to two or more essentially identical arrays on a substrate.
  • essentially identical electrode arrays or “essentially identical arrays” is meant that the dimensions and arrangement of electrodes, electrode structures, and electrode elements is the same for the referenced arrays.
  • two essentially identical electrode arrays will have electrode structures ofthe same dimensions (length, width, thickness), where the electrode structures have the same number of electrode elements, and the arrangement of electrode structures and electrode elements in each array are the same.
  • arrangement is meant the distance between structures or elements (gap width), their physical position with respect to one another, and their geometry (angles, degree of curvature, circle-on-line or castellated geometries, etc.), including the same features of any electrode buses that may be connected to electrode structures or electrode elements.
  • Electrodes of essentially identical arrays also comprise the same materials. For the purposes of calculating trace resistances and cell index number, a subsfrate can have any number of essentially identical arrays.
  • the following discussion provides novel methods of calculating cell index of cells adliered to arrays of a cell-substrate impedance monitoring device and novel methods for the calculation ofthe resistances ofthe electrical connection traces leading to two or more electrode arrays of a cell-subsfrate impedance monitoring device.
  • Impedance (Z) has two components, namely the resistance Rs and reactance Xs.
  • the impedance Z is expressed as follows,
  • serial resistance and serial reactance are equivalent.
  • Those who are skilled in electrical and electronic engineering can readily derive one form of expression from the parameter values in the other expression.
  • serial resistance and serial reactance are simply called resistance and reactance.
  • monitoring cell-substrate impedance for detection or measurement of change in impedance can be done by measuring impedance in any suitable range of frequencies.
  • the impedance can be measured in a frequency range from about 1 Hz to about 100 MHz. In another example, the impedance can be measured in a frequency range from about 100 Hz to about 2 MHz.
  • the impedance is typically a function ofthe frequency, i.e., the impedance values change as frequency changes.
  • Monitoring cell-subsfrate impedance can be done either in a single frequency or multiple frequencies. If the impedance measurement is performed at multiple frequencies, then a frequency-dependent impedance spectrum is obtained - i.e., there is an impedance value at each measured frequency.
  • the impedance has two components - a resistance component and a reactance component. A change in either resistance component or reactance component or both components can constitute a change in impedance.
  • the method for the measurement of electrical (or electronic) impedance is achieved by , (1) applying a voltage between or among said electrodes at a given frequency (or multiple frequencies, or having specific voltage waveform) and monitoring the electrical current through said electrodes at the frequency (or multiple frequencies, or having specific waveform), dividing the voltage amplitude value by the current amplitude value to derive the impedance value; (2) applying an electric current of a single frequency component (or multiple frequencies or having specific current wave form) through said electrodes and monitoring the voltage resulted between or among said electrodes at the frequency (or multiple frequencies, or having specific waveform), dividing the voltage amplitude value by the current amplitude
  • the “division” is done for the values of current amplitude and voltage amplitude at same frequencies.
  • the current amplitude and voltage amplitude are expressed in the form of complex numbers, which take into account of how big the current and the voltage are and what the phase difference between the sinusoidal waves ofthe current and the voltage is.
  • the impedance value is also expressed in a complex form, having both resistance and reactance component, as shown in equations above.
  • the measured cell-subsfrate impedance can be used to calculate a parameter termed Cell Index or Cell Number Index.
  • Various methods for calculating such a cell number index can be used based on the changes in resistance or reactance when cells are attached to the electrode structures with respect to the cases no cells are attached to the elecfrode structures.
  • the impedance (resistance and reactance) ofthe electrode structures with no cell attached but with same cell culture medium over the electrode structures is sometimes referred as baseline impedance.
  • the baseline impedance may be obtained by one or more ofthe following ways: (1) the impedance measured for the electrode structures with a cell-free culture medium introduced into the well containing the electrode structures, wherein the culture medium is the same as that used for the impedance measurements for the condition where the cell attachment is monitored; (2) the impedance measured shortly (e.g. 10 minutes) after the cell-containing medium was applied to the wells comprising the electrode structures on the well bottom (during the short period after cell-containing medium addition, cells do not have enough time to attach to the electrode surfaces.
  • the length of this short-period may depend on cell type and/or surface treatment or modification on the electrode surfaces); (3) the impedance measured for the elecfrode structures when all the cells in the well were killed by certain treatment (e.g. high-temperature treatment) and/or reagents (e.g. detergent) (for this method to be used, the freatment and/or reagents should not affect the dielectric property ofthe medium which is over the electrodes).
  • the cell index or cell number index can be calculated by: (Al) at each measured frequency, calculating the resistance ratio by dividing the resistance ofthe electrode arrays when cells are present and/or attached to the electrodes by the baseline resistance,
  • Cell Index is derived as
  • R ceU (f t ) is the resistance (cell-subsfrate resistance) ofthe electrode arrays or electrode structures when the cells are present on the electrodes at the frequency ⁇ and R b (f t ) is the baseline resistance ofthe electrode array or structures at the frequency fi.
  • the cell index obtained for a given well reflects: 1) how many cells are attached to the electrode surfaces in this well, 2) how well cells are attached to the electrode surfaces in the well._
  • a zero or near-zero "cell index or cell number index” indicates that no cells or very small number of cells are present on or attached to the electrode surfaces, hi other words, if no cells are present on the electrodes, or if the cells are not well-attached onto the electrodes, R ⁇ a (j is about the same as R b (f ( ) , leading to Cell
  • Cell Index is a quantitative measure of cell number present in a well.
  • a higher value of "cell index” may also indicate that, for same type ofthe cells and same number ofthe cells, cells are attached better (for example, cells spread out more, or cell adhesion to the electrode surfaces is stronger) on the electrode surfaces.
  • change in a cell status will lead to a change in cell index.
  • an increase in cell adhesion or a cell spread leading to large cell/electrode contact area will result in an increase in R cell (/) and a larger Cell Index.
  • a cell death or toxicity induced cell detachment, cell rounding up will lead to smaller R cell (f) and thus smaller Cell Index.
  • the cell number index can be calculated by:
  • a zero or near-zero "cell number index” indicates that no cells or very small number of cells are present on or attached to the elecfrode surfaces.
  • a higher value of "cell number index” indicates that, for same type ofthe cells and cells under similar physiological conditions, more cells are attached to the electrode surfaces.
  • the cell index can be calculated by: (CI) at each measured frequency, subtracting the baseline resistance from the resistance ofthe electrode arrays when cells are present or attached to the electrodes to determine the change in the resistance with the cells present relative to the baseline resistance;
  • cell-number index is derived based on the maximum change in the resistance across the measured frequency range with the cells present relative to the baseline resistance. This cell index would have a dimension of ohm.
  • the cell index can be calculated by: (Dl) at each measured frequency, calculating the magnitude ofthe impedance
  • cell-number index is derived based on the maximum change in the magnitude ofthe impedance across the measured frequency range with the cells present relative to the baseline impedance. This cell index would have a dimension of ohm.
  • the index can be calculated by: (El) at each measured frequency, calculating the resistance ratio by dividing the resistance of elecfrode arrays when cells are present or attached to the electrodes by the baseline resistance,
  • cell-number index is derived based on multiple-frequency points, instead of single peak-frequency like above examples.
  • a zero or near-zero “cell number index” indicates that on cells are present on the electrodes.
  • a higher value of “cell number index” indicates that, for same type ofthe cells and cells under similar physiological conditions, more cells are attached to the electrodes.
  • the cell index can be calculated by: (FI) at each measured frequency, subtracting the baseline resistance from the resistance ofthe electrode arrays when cells are attached to the electrodes to determine the change in the resistance with the cells present relative to the baseline impedance; (here the change in the resistance is given by
  • AK(/,) R s - ce i fi) - R s - bas u, fi) for the frequency / admir
  • R s _ cell and R s _ baseline are the serial resistances with the cells present on the elecfrode array and the baseline serial resistances, respectively); (F3) analyzing the frequency dependency ofthe change ofthe resistance to derive certain parameters that can quantify such dependency, hi one example, such parameters can be calculated as . hi another example, such parameter can be calculated as ⁇
  • the parameter(s) are used as cell index or cell i number index. hi this case, "cell-number index" is derived based on the analysis ofthe frequency spectrum ofthe change in the resistance. Depending how the parameters are calculated, the cell index may have a dimension of ohm.
  • the cell index can be calculated by:
  • cell-number index is derived based on the analysis ofthe frequency spectrum ofthe change in the magnitude ofthe impedance. Depending how the parameters are calculated, the cell index may have a dimension of ohm.
  • deriving "cell index” or “cell number index” and using such index to monitor cell conditions may have advantages. There are several advantages of using "cell number index” to monitor cell growth and/or attachment and/or viability conditions.
  • calibration curve for depicting the relationship between the cell number and the cell number index by performing impedance measurements for different number of cells added to the electrodes (in such an experiment, it is important to make sure that the seeded cells have well-attached to the electrode surfaces).
  • cell number index can also be used to compare different surface conditions. For the same electrode geometry and same number of cells, a surface freatment given a larger cell number index indicates a better attachment for the cells to the elecfrode surface and/or better surface for cell attachment.
  • the impedance ofthe electrode array (with or without cells present on the electrodes) is given by
  • Z Smtch is the impedance of electronic switch at its on stage
  • Z /race is the impedance ofthe electrical connection traces (or electrical conductive traces) on the substrate between the connection pads and the electrode buses
  • Z ma ⁇ is the total impedance measured at the impedance analyzer.
  • a method is invented in the present application to determine the impedance of electrical conductive (electrical connection) traces (mainly trace resistance, trace reactance is very small for the thin conductive film trace) based on the relationships among two or more essentially identical arrays on a cell-subsfrate impedance monitoring
  • connection traces 15 connection traces.
  • the impedance determined from the impedance analyzer does contain both resistance (serial resistance, R total ) and reactance (serial reactance).
  • R total the measured total resistance
  • R fr - ce the resistance of electrical conductive (connection) trace
  • R switch switch resistance
  • e-anay-C "total-C ⁇ "trace-C ⁇ "switch-C (°C)
  • e-array-D "total-D ⁇ trace-D ⁇ "switch -D (°D)
  • R-switch-B ' Rnvitch-c an d R-switch-D nave ver y similar values and can be assumed to be the same, R ⁇ lw7fA .
  • the known parameters are R tota ,_ ⁇ , R t0 , a ⁇ - B » RMai-c > md
  • Each trace resistance (R trace _ A , tmce . B , R trace - and R tmce _ D ) depends on the metal film type used, and the geometry ofthe trace such as the how many rectangular segments the trace has, the film thickness(es) ofthe segments, the width(s) ofthe segments, the length(s) ofthe segment(s). For example, trace-A where N is the number ofthe segments ofthe trace- A, t A .
  • t , d A - t and ⁇ A - I is the thickness, width and length of the i-th segment of the traces for the electrode array A, and p is the resistivity ofthe thin film.
  • the equation here applies to the film comprising a single type of metal.
  • the equation can be readily modified to be applicable to the film comprising two or more metal types (e.g. gold film over chromium adhesion layer).
  • the relationship among the trace resistances is simply determined by the pre-determined geometrical shapes (e.g. the length, width of the segments). For example, it would be straightforward to calculate the ratio a A _ D between the resistance ofthe electrically conductive traces for the electrode array A to the resistance ofthe electrically conductive traces for the electrode array D as below, where the film thickness is assumed to be the same everywhere on these traces and the resistivity is also the same everywhere on these traces,
  • equations (6A)-(6D) can be re-written in the following format: e-array- ⁇ ⁇ total- A ⁇ A-D * trace-D ⁇ switch (10A)
  • Electrode-arrays A through D have essentially identical electrode structures, the electrode array resistances R e _ ⁇ rr ⁇ y _ A , R e - ⁇ rr ⁇ y - B ,
  • R e - ⁇ rr y -c & R e - ⁇ rr ⁇ y - D should be of same, or very similar value for such a condition when all the elecfrode arrays are exposed to the same biological or chemical solutions or suspensions, i.e.: R e _ ⁇ rmy _ A « R e _ ⁇ rmy . B « R e - ⁇ rr ⁇ y .
  • trace-D ' "e-array J [ “e-array ⁇ " total- A ⁇ ® A ⁇ D”trace-D ⁇ ⁇ switch ) ⁇ ⁇ e-array ⁇ ⁇ total-C ⁇ a C-D trace-D ⁇ switch ) ⁇ +
  • F(R tmce _ D ,R e _ array ) is the sum ofthe squared-differences between the two-sides ofthe approximate equality in (11 A, 1 IB, 1 IC and 1 ID).
  • Equations (13 A) and (13B) can be re-written as
  • a n [a A _ D + a B _ D + c _ D + l];
  • the trace resistances of R trace- A ' R ttrraaccee--BB ⁇ R trace-C can be calculated using equations (9B), (9C) and (9D).
  • the elecfrode array resistance R e - anay -A ⁇ > "e- arr ay-B R e_-a réeller,rcounta,y necessarily- rC a t n J - i d vJ - R "e .- meticulousar m ra n y,-D n can be calculated from the measured resistance R total _ A , R tote/ _ B .
  • R tota i-c and R m a i- D respectively using equations (10A), (10B), (10C) and (10D).
  • one aspect ofthe present invention is directed to a method of calculation of the resistances ofthe electrical connection fraces s from the measured, total resistances for two or more essentially identical electrode arrays (such as, for example arrays A-D in Figure 1), comprising the following steps:
  • Another aspect ofthe present invention is directed to a method of calculating the resistance ofthe electrode arrays from the measured, total electrode resistances for two ro more essentially identical electrode arrays (such as, for example arrays A-D in Figure 1) if the same or similar solutions or suspensions are added to be in contact with the electrode assays, comprising the following steps:
  • the solutions or suspensions (for example, cell suspension) applied to each electrode array may have different compositions.
  • cell suspensions of different cell numbers may be used so that the suspensions applied to each electrode array are quite different.
  • the determination ofthe resistance ofthe electrode arrays with the cells present would require the determination ofthe resistance ofthe electrical connection traces by performing a "reference run” or “calibration run” in which the elecfrode arrays are exposed to a same, reference solution. From the "reference run", the resistances ofthe electrical connection traces can be determined.
  • the elecfrode arrays are exposed to the solutions or cell suspensions of interest and the resistances for the electrode arrays under such conditions are measured with an impedance analyzer or impedance measuring circuit.
  • the resistance ofthe electrode arrays with such cell suspensions present can be determined (or continuously determined) from the measured resistance by subtracting the sum ofthe resistance ofthe electronic switches and the resistance ofthe electrical connection traces for corresponding electrode arrays from the measured resistances.
  • another aspect ofthe present invention is directed to a method of calculating the resistance ofthe electrode arrays from the total electrical resistances measured at an impedance analyzer for essentially identical electrode arrays (such as electrode arrays A-D in Figure 1 used as an example) if different solutions or suspensions of interest are applied to the elecfrode assays, comprising the following steps:
  • step (1), (2) and (3) the steps of exposing the electrode arrays to reference solutions for the determination ofthe resistances of electrically conductive traces may be performed before or after the steps of applying the solutions or suspensions of interest to the elecfrode arrays and measuring the total electrical resistance (step (4)).
  • step (4) may be performed first. After that, the solutions or suspensions ofthe interest may be removed from the electrode array. The reference solutions can then be added to the electrode arrays (step (1)).
  • step (2) and step (3) can be then performed to determine the resistances of electrical connection traces.
  • Step (5) can be done. ha another approach, step (1) and (2) can be performed ahead of step (4).
  • Another aspect ofthe present invention is directed to a method of determining the resistance ofthe electrode arrays with the cells present for a cell-based assay based on the total electrical resistance measured at an impedance analyzer for essentially identical electrode arrays.
  • the electrode arrays are exposed to a same, reference solution (for example, a same cell culture medium that does not contain any cells) and electrical measurement is conducted to determine the resistance of electrical connection traces.
  • electrical resistances ofthe electrode arrays with cell suspensions added to elecfrode arrays can be calculated from the total electrical resistances measured at an impedance analyzer.
  • Such total electrical resistance would include the resistance ofthe elecfrode anays with cells present, the resistance of electronic switches and the resistance of electrical connection traces.
  • the method comprises following steps
  • step (1), (2) and (3) the steps of exposing the electrode anays to reference solution for the determination ofthe electrical resistance of electrically conductive fraces (step (1), (2) and (3)) may be performed before or after the steps of applying the solutions of interest or cell suspensions of interest to the electrode arrays and measuring the total electrical resistance (step (4)).
  • step (4) may be performed first, followed by steps (1) and (2).
  • the cell suspensions ofthe interest may be removed from the electrode anay.
  • reference solutions can be added to the elecfrode anays.
  • step (4) the cells are all lysed with some cell lysis solutions so that the electrodes are exposed to the same, reference solutions for the measurement and calculation of step (2) and (3).
  • step (5) is performed to determine the electrical resistance of elecfrode anays with the cell suspensions of interest present.
  • the determination ofthe resistances ofthe electrical conductive traces for the electrode arrays that essentially identical electrode anays may be, or may not be, part of the monitoring of cell-substrate impedance for cell-based assays. It depends on how the impedance data (measured at a single frequency or multiple frequencies, measured at multiple time points) ofthe electrode anays is analyzed. In some assays, one is interested in the relative change in the resistance or impedance ofthe electrode anays with the cells present relative to the baseline resistance or impedance.
  • the resistance (or impedance) ofthe electrode anays is prefened to determine the resistance (or impedance) ofthe electrode anays from the total, measures resistance (or impedance) by subtracting the resistance ofthe electrical conductive traces and the resistance of electronic switches.
  • determination of the resistances or impedance ofthe electrically conductive traces may be required.
  • the resistances ofthe electrically conductive traces are needed, in order to remove the effect ofthe resistance ofthe electrically conductive fraces on the analysis ofthe relative change ofthe resistance or impedance.
  • the Cell Index calculation method (F) described above there is no need to determine the resistances ofthe electrically conductive traces since the effect ofthe resistance ofthe electrically conductive traces is canceled out in the calculations.
  • the monitoring ofthe cell-subsfrate impedance may be or may not be based on the change with respect to the baseline impedance (or resistance).
  • a cell- based assay is performed to assess the effect of a test compound on the cells.
  • One method in performing such an assay is by monitoring ofthe cell-subsfrate impedance and determining the change in the cell-subsfrate impedance before and after the addition of the test compound to the cells.
  • the monitoring of cell-subsfrate impedance can be performed at a single frequency point or multiple frequency points, at a single time point or multiple time points after drug addition.
  • the impedance is first measured at a single frequency or multiple frequencies for the electrode anays with the cells present just before addition of test compound. The test compound is then added to the cells.
  • the impedance is then measured again at the same single frequency or multiple frequencies for the electrode anays with the cells after the addition of test compound.
  • post-compound addition measurement may be performed for many time points continuously in a regular or inegular time intervals.
  • the change in the cell-subsfrate impedances can be determined or quantified by subtracting the impedance(s) (resistance and/or reactance) measured before addition ofthe test compound from the impedance(s) (resistance and or reactance) measured after addition ofthe test compound.
  • a single parameter or multiple parameters may be further derived for each time point after compound addition based on the calculated change in the cell-substrate impedances.
  • Such parameters are used to quantify the cell changes after compound addition.
  • Such approaches can be used further to analyze the responses ofthe cells to a test compound at multiple concentrations to derive dose-dependent response curves.
  • Normalized Cell Index a "Normalized Cell Index" at a given time point is calculated by dividing the Cell
  • Normalized Cell Index is 1 at the reference time point.
  • Normalized cell index is cell index normalized against cell index at a particular time point, hi most cases in the present applications, normalized cell index is derived as normalized relative to the time point immediately before a compound addition or treatment. Thus, normalized cell index at such time point (immediately before compound addition) is always unit one for all wells.
  • One possible benefit for using such normalized cell index is to remove the effect from difference in cell number in different wells. A well having more cells may produce a larger impedance response following compound freatment. Using normalized cell index, it helps to remove such variations caused by different cell numbers.
  • a "delta cell index" at a given time point is calculated by subtracting the cell index at a standard time point from the cell index at the given time point.
  • the delta cell index is the absolute change in the cell index from an initial time (the standard time point) to the measurement time.
  • the time-dependent cellular response may be analyzed by deriving parameters that directly reflect the changes in cell status.
  • time dependent celluler response may be analyzed by calculating the slope of change in the measured impedance responses (that is equivalent to the first order derivative ofthe impedance response with respect to time, impedance response here can be measured impedance data or derived values such as cell index, normalized cell index or delta cell index).
  • the time-dependent cellular responses (including cytotoxicresposnes) responses may be analyzed for their higher order derivatives with respect to time. Such high order derivatives may provide additional information as for how cells responding to different compounds and as for the mechanisms of compound action.
  • Cell Change Index a parameter that can effectively link time dependent cell index I with cell status
  • CCI is the normalized rate of change in cell index.
  • CCI values can be used to quantify the cell status change.
  • the cell index determined by a cell-subsfrate impedance monitoring system described herein is expected to be a proportionate measure ofthe cell number in the well since the cell morphology and average extent of cell adhesion to the electrode surfaces among the whole cell population do not exhibit significant changes over time.
  • the cell index (CI) increase with time following an exponential function, such that
  • CCI is about 0.7/DT
  • cell index increases in the same rate as that expected for an exponential growth ofthe cells.
  • CCI » 0.7/DT cell index increases faster than that expected for an exponential growth (or log growth) ofthe cells. This indicates that cells may grow faster than regular exponential growth, or cells may exhibit some morphology change (e.g. cell spreading out or adhering better to the elecfrode surfaces), leading to large impedance signal, or both of above effects, or there may be other cell behaviors occurring particular to the assay or culture conditions.
  • cell index increases in the rate slowed than that expected for an exponential growth. This indicates that cell growth rate may be slowed down relative to exponential growth, or cell growth may be somewhat inhibited by chemical compounds added to the culture media or by other cell culture parameters, or that certain populations of cells are dying off and detaching from the electrode surfaces, or there may be other cell behaviors occurring particular to the assay or culture conditions.
  • CCI is about zero, then cell index shows a near constant value. This may indicate that the cell growth is nearly-completely inhibited. For example, all the cells are anested at certain points of cell cycle and are not progressing further. Or, this may indicate that the number of cells dying off in the culture is nearly as the number of newly-divided cells. Alternatively this may indicate that cells reach stationary phase of cell culture. Alternatively this may indicate that number of cells are above the detection upper limit ofthe cell-substrate impedance monitoring system. There is also the possibility of other cell behaviors occurring particular to the assay or culture conditions. (5) If CCI is negative, then the cell index is decreasing with time, showing the cells losing attachment to the electrode surface or changing their morphology. (6) If CCI is very negative, then the cell index decreases rapidly with time, showing that either cells lose attachment to the elecfrode surfaces quickly or cells change their morphology very quickly. D. Methods for performing real-time cell-based assays
  • the present invention provide cell-based assays that can be performed in real time to assess cell proliferation, cell growth, cell death, cell morphology, cell membrane properties (for example, size, morphology, or composition ofthe cell membrane) cell adhesion, and cell motility.
  • the assays can be cytotoxicity assays, proliferation assays, apoptosis assays, cell adhesion assays, cell activation or stimulation assays, anticancer compound efficacy assays, receptor-ligand binding or signal transduction analysis, assays of cytoskeletal changes, assays of cell structural changes (including but not limited to, changes in cell membrane size, morphology, or composition), cell quantification, cell quality control, time-dependent cytotoxicity profiling, assays of cell differentiation or de- differentiation, detection or quantitation of neutralizing antibodies, specific T-cell mediated cytotoxic effect assays, assays of cell adhesivity, assays of cell-cell interactions, analysis of microbial, viral, or environmental toxins, etc.
  • the assays are real-time assays in the sense that cell behavior or cell status being assayed can be assessed continuously at regular or irregular intervals.
  • Cell behaviors, cell responses, or cell status can be assayed and the results recorded or displayed within seconds to minutes of their occunence.
  • the cell response during an assay can be monitored essentially continuously over a selected time period. For example, a culture can be monitored every five to fifteen minutes for several hours to several days after addition of a reagent.
  • the interval between impedance monitoring, whether impedance monitoring is performed at regular or irregular intervals, and the duration ofthe impedance monitoring assay can be determined by the experimenter.
  • the cell-based impedance assays ofthe present invention avoid inadvertently biased or misleading evaluation of cell responses due to the time point or time points chosen for sampling or assaying the cells, hi addition, the assays do not require sampling of cell cultures or addition of reagents and thus eliminate the inconvenience, delay in obtaining results, and enor introduced by many assays.
  • Patent Application No. 10/987,732 United States patent application numberl0/705,615,entitled “Impedance based apparatuses and methods for analyzing cells and particles", filed on November 10, 2003, all incorporated herein by reference for their disclosure of cell-subsfrate impedance devices, systems, and methods of use. Additional details of cell-substrate impedance monitoring technology is further disclosed in the present invention.
  • cell-subsfrate impedance monitoring devices are used that have microelectrode arrays with appropriate geometries fabricated onto the bottom surfaces of wells such as microtiter plate wells, or have a similar design of having multiple fluid containers (such as wells) having electrodes fabricated on their bottom surfaces facing into the fluid containers.
  • Cells are introduced into the fluid containers of the devices, and make contact with and attach to the electrode surfaces. The presence, absence or change of properties of cells affects the electronic and ionic passage on the electrode sensor surfaces. Measuring the impedance between or among electrodes provides important information about biological status of cells present on the sensors.
  • analogue electronic readout signals can be measured automatically and in real time, and can be converted to digital signals for processing and for analysis.
  • cell-subsfrate impedance assays are performed using a system ofthe present invention that comprises a device ofthe present invention, an impedance monitor, a device station that comprises electronic circuitry and engages the device and the impedance analyzer, and a software program that controls the device station and records and analyzes impedance data.
  • a cell index can optionally be automatically derived and provided based on measured electrode impedance values.
  • the cell index obtained for a given well reflects: 1) how many cells are attached to the electrode surfaces in this well, and 2) how well (tightly or extensively) cells are attached to the electrode surfaces in this well.
  • the more the cells of same type in similar physiological conditions attach the electrode surfaces the larger the cell index.
  • the better the cells attach to the electrode surfaces e.g., the cells spread-out more to have larger contact areas, or the cells attach tighter to electrode surfaces, the larger the cell index.
  • a method for performing cell- based assays comprising: a) providing a cell-substrate impedance monitoring device of the present invention that comprises two or more electrode anays, each of which is associated with a fluid container ofthe device; b) attaching the device to an impedance monitor; c) introducing cells into one or more fluid containers ofthe device; and d) monitoring cell-subsfrate impedance of at least one ofthe fluid containers that comprises an electrode anay and cells.
  • impedance is monitored from the at least one fluid container to obtain impedance measurements at at least three time points.
  • impedance measurements or impedance values derived from impedance measurements from at least three time points are plotted versus time to generate one or more impedance curves for the one or more fluid containers.
  • a method for performing cell-based assays in an impedance-monitoring system comprising: a) providing a cell- subsfrate impedance monitoring system ofthe present invention that comprises a device having two or more electrode anays, each of which is associated with a well ofthe device; b) introducing cells into one or more wells ofthe device; and c) monitoring cell- subsfrate impedance of at least one ofthe wells that comprises an elecfrode anay and cells.
  • impedance is monitored from the one or more wells ofthe device to obtain impedance measurements at at least three time points.
  • impedance measurements or impedance values derived from impedance measurements from at least three time points are plotted versus time to generate one or more impedance curves for the one or more wells.
  • the method can be used to assay cell status, where cell status includes, but is not limited to, cell attachment or adhesion status (e.g. the degree of cell spread, the attachment area of a cell, the degree of tightness of cell attachment, cell morphology) on the substrate including on the electrodes, cell growth or proliferation status; number of viable cells and/or dead cells in the well; cytoskeleton change and re-organization and number of cells going through apoptosis and/or necrosis.
  • cell attachment or adhesion status e.g. the degree of cell spread, the attachment area of a cell, the degree of tightness of cell attachment, cell morphology
  • the cell-based assays that be performed with above methods include, but are not limited to, cell adhesion, cell apoptosis, cell differentiation, cell proliferation, cell survival, cytotoxicity, cell morphology detection, cell quantification, cell quality control, time-dependent cytotoxicity profiling, IgE-mediated cell activation or stimulation, receptor-ligand binding, viral and bacterial toxin mediated cell pathologic changes and cell death, detection and quantification of neutralizing antibodies, specific T-cell mediated cytotoxic effect, and cell-based assays for screening and measuring ligand-receptor binding.
  • cells are added to at least two fluid containers of a device, each of which comprises an electrode anay, and impedance is monitored from at least two wells that comprise cells and an electrode anay.
  • the cells used in the assay can be primary cells isolated from any species or cells of cell lines.
  • Primary cells can be from blood or tissue.
  • the cells can be engineered cells into which nucleic acids or proteins have been introduced.
  • different cell types are added to different wells and the behavior ofthe cell types is compared.
  • An impedance monitoring assay can be from minutes to days or even weeks in duration. Preferably, impedance is monitored at three or more time points, although this is not a requirement ofthe present invention. Impedance can be monitored at regular or inegular time intervals, or a combination of hregular and regular time intervals, hi one embodiment of a cell-based impedance assay, the cell-substrate impedance is monitored at regular time intervals, hi some embodiments ofthe present invention, impedance is monitored at inegular intervals and then at regular intervals during a particular time window ofthe assay. Impedance can be momtored at one frequency or at more than one frequency.
  • impedance is monitored over a range of frequencies for each time point at which impedance is monitored.
  • impedance is monitored at at least one frequency between about 1 Hz and about 100 MHz, more preferably at at least one frequency between about 100 Hz and about 2 MHz.
  • the present invention provides a method for performing real-time cell-based assay investigating the effect of a compound on cells, comprising: a) providing an above described system; b) seeding the cells to the wells of multiple- well devices; c) adding the compound to the wells containing cells; d) monitoring cell- subsfrate impedance before and after adding the compound at a regular or inegular time interval; wherein the time dependent impedance change provides information about time dependent cell status before addition ofthe compound and about time dependent cell status under the interaction ofthe compound.
  • Information about cell status includes, not limited to, cell attachment or adhesion status (e.g.
  • Information about cell status may also include any compound-cell interaction leading to any change to one or more of above cell status indicators. For example, if the compound binds to a receptor on the cell surface and such binding leads to a change in cell morphology, then the binding of compound to the receptor can be assayed by the monitored cell-substrate impedance.
  • the cell-based assays that be performed with above methods include, but not limited to, cell adhesion, cell apoptosis, cell differentiation, cell proliferation, cell survival, cytotoxicity, cell morphology detection, cell quantification, cell quality control, time-dependent cytotoxicity profiling, IgE-mediated cell activation or stimulation, receptor-ligand binding, viral and bacterial toxin mediated cell pathologic changes and cell death, detection and quantification of neutralizing antibodies, specific T-cell mediated cytotoxic effect, cell-based assay for screening and measuring ligand-receptor binding.
  • the cell-subsfrate impedance is monitored at regular time intervals.
  • the impedance is measured at a regular 2 hour, 1 hour, 30 min or 15 min time interval before and after adding the compound.
  • a real-time assay means that one can perform the measurement on cell-subsfrate impedance with various time resolutions, for example, measurement taking place at a longer time interval such as every hour or every two hours, or at a shorter time interval every minute or a few minutes.
  • Real-time assay does not mean that the measurements are provided in a continuous, uninterrupted fashion. In another word, real-time assay does not mean that the measurements are performed at every single moment.
  • Figure 2 depicts results ofthe use of methods ofthe present invention to monitor cell proliferation.
  • H460 cells were introduced into wells of a 16 well device of a cell-subsfrate impedance monitoring system ofthe present invention, with different wells receiving different initial cell seeding numbers.
  • the device was engaged with a device station ofthe system that was in a tissue culture incubator that kept a temperature of 37 degrees C and an atmosphere of 5% CO 2 .
  • Cell-subsfrate impedance was monitored at 15 minute intervals for 125 hours.
  • the cell index was calculated by the system for each time point and displayed as a function of time to give cell growth
  • Figure 3 depicts results of real-time monitoring of cell attachment and spreading of NIH3T3 cells.
  • the cells were seeded onto cell-subsfrate impedance monitoring devices ofthe present invention that were coated with either poly-L-lysine or fibronectin.
  • the device was connected to a device station that was in a tissue culture incubator that kept a temperature of 37 degrees C and an atmosphere of 5% CO 2 .
  • Cell attachment and cell spreading on the difference coating surfaces were monitored by measuring impedance on the cell-subsfrate monitoring system. Impedance was monitored in real time every 3 minutes for 3 hours. The cell index for each time point was calculated by the impedance monitoring system and plotted as a function of time.
  • FIG. 4 shows the results of an experiment monitoring morphological changes in Cos-7 cells in response to stimulation with epidermal growth factor (EGF).
  • EGF epidermal growth factor
  • the present invention provides methods for performing cell proliferation assays.
  • an increase in monitored impedance is indicative of an increases cell number.
  • the impedance measurements or impedance values derived from impedance measurements can be plotted versus time to obtain growth curves for cells growing in a fluid container of a cell-subsfrate monitoring device ofthe present invention.
  • the present invention provides a method of generating at least one cell growth curve, comprising: providing a device ofthe present invention having two or more electrode arrays, each of which is associated with a fluid container ofthe device; attaching the device to an impedance analyzer; adding cells to one or more fluid containers ofthe device; monitoring impedance from the one or more fluid containers to obtain impedance measurements at three or more time points after adding the cells to the one or fluid containers; and plotting the impedance measurements or values for the three or more time points versus time to generate at least one growth curve for the cells in the one or more fluid containers.
  • the present invention also provides a method of generating at least one growth curve using a system ofthe present invention, where the system includes a multi-well cell-substrate impedance monitoring device, an impedance analyzer, a device station, and a software program.
  • the method includes; providing a multi-well cell-substrate impedance measuring system; adding cells to one or more wells ofthe system; monitoring impedance from the one or more wells to obtain impedance measurements at three or more time points after adding cells to the one or more wells; and plotting impedance measurements or impedance values for the three or more time points versus time to generate a growth curve for the cells in the one or more wells.
  • impedance is monitored at four or more time points, in which at least one ofthe four or more time points is measured from a fluid container prior to adding cells to the fluid container.
  • impedance is monitored at regular or inegular time intervals for an assay period of from minutes to days.
  • proliferation assays can be performed by monitoring impedance for a period of between several hours and several days.
  • a plot can optionally be generated by plotting averaged impedance measurements of values at assayed time points for replicate wells versus time. Preferably, a standard deviation for the averaged values is also calculated.
  • a growth curve can be generated by plotting impedance measurements versus time, or by plotting cell index values that are calculated from impedance measurements, such as nonnalized cell index values or delta cell index values versus time.
  • the impedance measurement or cell index axis (typically the y-axis) can optionally use a log scale.
  • An impedance value can be any indices of impedance derived from impedance measurement, including, as nonlimiting examples, a cell index, a normalized cell index or a delta cell index.
  • impedance value can also be a "raw" measured or monitored impedance value.
  • Cell index (including normalized and delta cell index) can be a useful value for plotting growth curves, as it relates impedance measurements to cell number.
  • a delta cell index for a given time point can be derived by subtracting the cell index at a baseline point, such as a time point after cell attachment and just before log phase growth, from the cell index measurement at the given time point.
  • determinations of impedance values and generating growth curves based on impedance measurements or values can be performed by software, and preferably by software that interfaces directly with the impedance analyzer.
  • impedance values (where used) can be measured or derived or calculated and growth curves generated by a software program that controls and receives data from the impedance analyzer.
  • a growth curve generated from impedance measurements or cell index values (including normalized cell index values and delta cell index values) can optionally be used to calculate one or more kinetic parameters of cell growth or behavior.
  • a growth curve can be used to calculate the length of a lag phase, cell attachment time, cell attachment rate, or a cell doubling time.
  • Figure 2 shows real-time monitoring of proliferation of H460 cells seeded at different initial cell seeding numbers on a cell substrate impedance monitoring system ofthe presnet invention.
  • the cell proliferation was continuously recorded every 15 minutes for over 125 hours.
  • the cell growth curves in the log scale show exponential cell growth or cells in the stationary phase.
  • cell doubling time is the same as the cell index doubling time.
  • the cell doubling time (DT) is about 17.2 hrs.
  • Another simple method to calculate the cell index doubling time is just to figure out how long t takes cell index to double. For example, for the cell index curve with initial seeding density of 900 cells. It took about 17 hrs for cell index to change from 1.0 (at about 82 hrs) to 2.0 (at about 99 hrs). Thus the clel index doublimng time is 17 hrs.
  • Figure 3 shows real time monitoring of cell attachment and spreading of NIH3T3 cells using a cell-subsfrate imepdnace monitoring system ofthe presnet invention.
  • the cells were seeded onto devices coated with either poly- L-lysine or fibronectin.
  • the cell attachment and cell spreading processes on the different coating surfaces were monitored every 3 minutes for over 3 hours in real time.
  • cell attachment time The time it takes for cell index to increase from zero to a maximum value or a some-what constant value (assuming that there is no cell division or growth in this initial time period following cell seeding) is the cell attachment time.
  • cell attachment time in a fibronectin coated well is about 1.2 hrs, as compared with the attachment time of about 3.5 hrs for the same cells in a poly-L-lysine coated well.
  • Cell attachment rate is defined as 1 over the cell attachment time.
  • cell attachment rate is about 0.83 hr "l and about 0.29 hr "1, respectively, for NIH3T3 cells attaching to a fibronectin-coated well and a poly-L-lysine coated well.
  • Figure 4 shows real-time monitoring of morphological changes in Cos-7 cells uisng a cell-subsfrate impedance monitoring system ofthe presnet invention.
  • the cells were serum starved for 8 hours and stimulated with or without 50 ng/mL EGF. Changes in cell morphology were monitored at 3 min intervals for 2 hours and then 1 hour interval for 14 hours.
  • the initial jump in the signal in EGF-treated cells is due to membrane ruffling and actin dynamics in response to EGF.
  • the anow indicates the point of EGF stimulation.
  • Using the cell index curve showing in Figure 4, we can calculate the cell attachment time and cell attachment rate. Mtial cell index increase immediately following cell addition to the ells (at time 0 in Figure 4) reflects the cell spreading and attachment process.
  • the time it takes for cell index to increase from zero to a maximum value or a some-what constant value (assuming that there is no cell division or growth in this initial time period following cell seeding) is the cell attachment time.
  • the cell attachment time is about 4 hrs.
  • Cell attachment rate, as defined: 1 over the cell attachment time, is about 0.25 hr _1 for Cos-7 cells.
  • Two or more cell types can be seeded to separate wells in a proliferation assay using the methods ofthe present invention to generate growth curves ofthe two or more cell types.
  • the growth curves or kinetic parameters derived from the growth curves ofthe cell types can be compared.
  • the invention includes a method of generating growth curves for at least two cell types, comprising: providing a device ofthe present invention having two or more electrode anays, each of which is associated with a fluid container ofthe device; attaching the device to an impedance analyzer; adding cells of two or more cell types to two or more fluid containers ofthe device, in which at least one ofthe two or more fluid containers receives one cell type and at least one other ofthe two or more fluid containers receives a different cell type, to provide two or more fluid containers comprising two or more different cell types; monitoring impedance from the two or more fluid containers comprising different cell types at three or more time points after adding the two or more cell types to the two or more fluid containers; and plotting impedance measurements or impedance values for the three or more time points versus time to generate a growth curve for the two or more cell types.
  • the present invention also provides a method of generating at least one growth curve using a system ofthe present invention, where the system includes a multi-well cell-subsfrate impedance monitoring device, an impedance analyzer, a device station, and a software program.
  • the method includes; providing a multi-well cell-subsfrate impedance measuring system; adding cells of two or more cell types to two or more wells ofthe device, in which at least one ofthe two or more wells receives one cell type and at least one other ofthe two or more wells receives a different cell type, to provide two or more wells comprising two or more different cell types; monitoring impedance from the two or more wells comprising different cell types at three or more time points after adding the two or more cell types to the two or more wells; and plotting impedance measurements or impedance values for the three or more time points versus time to generate a growth curve for the two or more cell types.
  • impedance is preferably monitored using an impedance monitoring device or system at four or more time points, in which at least one ofthe four or more time points is measured from fluid containers prior to adding cells to the fluid containers.
  • impedance is monitored at regular or inegular time intervals for an assay period of from minutes to days, for example, for a period of between several hours and several days.
  • a plot can optionally be generated by plotting averaged impedance measurements of values at assayed time points for replicate wells versus time.
  • a standard deviation for the averaged values is also calculated.
  • Impedance or impedance values such as cell index, normalized cell index, or delta cell index can be plotted versus time.
  • the impedance measurement or cell index axis (typically the y-axis) can optionally use a log scale.
  • a growth curve can be used to calculate the duration of a lag phase, cell attachment time, cell attachment rate, or a cell doubling time.
  • the growth curves ofthe two or more different cell types, or kinetic parameters derived from the growth curves ofthe two or more different cell types are compared to determine differences among the cell types in proliferation patterns or rates, or in kinetic parameters that can be derived from growth curves.
  • the different cell types used can be any cell types, including primary cells isolated from blood or tissue of an animal or human, or cells from cell lines.
  • proliferation rates of two types of primary cancer cell can be compared, or of primary cancer cells ofthe same type but different grades.
  • primary cells of individuals of different genotypes can be compared.
  • proliferation rates of primary or cell line stem cells can be compared.
  • growth curves or parameters of control and genetically modified cells of a cell line can be compared.
  • growth curves or parameters of cells infected with virus and control cells can be compared.
  • the present invention also includes a method of quantifying cells, comprising: providing a device ofthe present invention having two or more electrode anays, each of which is associated with a fluid container ofthe device; attaching the device to an impedance analyzer; adding cells to one or more fluid containers ofthe device; monitoring impedance from the one or more fluid containers to obtain impedance measurements at one or more time points after adding the cells to the one or more fluid containers; deriving a cell index for the one or more time points; and using the cell index to determine the number of cells in the one or more fluid containers at at least one ofthe one or more time points.
  • the cell index is used to determine the number of cells using a formula that relates cell index to cell number, in which the formula is obtained by: providing a device for cell-substrate monitoring, attaching the device to an impedance monitor; adding cells to one or more fluid containers ofthe device; measuring impedance ofthe one or more fluid containers comprising cells; calculating a cell index from the impedance measurements; determining the number of cells of said at least one fluid container at the time of impedance monitoring by a means other than impedance monitoring; and deriving a formula that relates the number of cells ofthe one or more fluid containers at the two or more time points with the impedance measurements at the two or more time points.
  • the number of cells introduced to the wells are pre-known or predetermined before cells are added in to the wells. Under such conditions, one assumes that there will be no change in cell number or little change in cell number when the impedance measurement for obtaining the formula is performed.
  • the number of cells determined by a method other than impedance monitoring can be determined by, for example, cell plating, hemacytometer counting, flow cytomefry, or Coulter counting.
  • the method can also be practiced using an impedance monitoring system ofthe present invention, where the system includes a multi-well cell-subsfrate impedance monitoring device, an impedance analyzer, a device station, and a software program.
  • the method includes; providing a multi-well cell-subsfrate impedance measuring system; adding cells one or more wells ofthe system; monitoring impedance from the one or more wells comprising cells at one or more time points after adding the cells to the one or more wells; deriving a cell index for the one or more time points; and using the cell index to determine the number of cells in said at least well at at least one of said one or more time points.
  • the cell index is used to determine the number of cells using a formula that relates cell index to cell number, in which the formula is obtained by: providing a system for cell-substrate monitoring, where the system comprises at least one multi-well cell- subsfrate impedance monitoring device, adding cells to one or more wells of a device of the system; measuring impedance ofthe one or more wells comprising cells at two or more time points; calculating a cell index from the impedance measurement at the two or more time points; determining the number of cells ofthe one or more wells at the two or more time points by a means other than impedance monitoring; and deriving a formula that relates the number of cells ofthe one or more wells at the two or more time points with the impedance measurements at the two or more time points.
  • the number of cells introduced to the wells are pre-known or predetermined before cells are added in to the wells. Under such conditions, one assumes that there will be no change in cell number or little change in cell number when the impedance measurement for obtaining the formula is performed.
  • the number of cells determined by a method other than impedance monitoring can be determined by, for example, cell plating, hemacytometer counting, flow cytomefry, or Coulter counting.
  • Formulas relating cell index (including normalized cell index and delta cell index, which can also be used) to cell number for a given cell type can be used to quantitate cells of that type in assays using a cell-substrate impedance monitoring device, such as a device described herein.
  • a cell-substrate impedance monitoring device such as a device described herein.
  • the derived formulas relating cell index to cell number can be used in subsequent assays. There is no need to obtain the formula each time when an assay is performed. However, it is worthwhile to point that the formula can only be valid as long as the cells are under same physiological conditions in the assays where the formula was derived and where the formula is used.
  • the formula will not hold.
  • the formula may not hold.
  • Another point worth mentioning here is that relates the fact the derived cell index or impedance also depends on cell attachment quality on the surface as well as cell morphology. If cell morphology or cell attachment changes during an assay, then one need to distinguish between the changes caused by change in cell number or in cell morphology or in cell attachment.
  • the present invention provides a method for performing a cell-based assay investigating the effect of one or more test compounds on cells, comprising: providing a device ofthe present invention having two or more electrode anays, each of which is associated with a fluid container ofthe device; attaching the device to an impedance analyzer; introducing cells into two or more fluid containers of the device that comprise an electrode anay; adding at least one test compound to at least one ofthe one or more ofthe fluid containers comprising cells and an electrode array to provide at least one test compound fluid container; providing at least one confrol fluid container to which cells are added that does not receive test compound; and monitoring cell-substrate impedance ofthe one or more test compound fluid containers and the one or more confrol fluid containers at at least three time points after adding the one or more test compounds, and analyzing impedance measurements from the one or more test compound fluid containers and the one or more confrol fluid containers at at least three time points after adding the one
  • the present invention also provides a method for performing a cell-based assay investigating the effect of one or more test compounds on cells, where the system includes a multi-well cell-subsfrate impedance monitoring device, an impedance analyzer, a device station comprising electronic circuitry that engages the device and connects the two or more electrode anays ofthe device to the impedance analyzer, and a software program that controls the device station and can record and analyze data from the impedance analyzer.
  • the method includes; providing a multi-well cell-substrate impedance measuring system; introducing cells into two or more wells of the device; adding at least one test compound to at least one ofthe one or more ofthe wells comprising cells to provide at least one test compound well; providing at least one control well to which cells are added that does not receive test compound; monitoring cell-subsfrate impedance ofthe one or more test compound wells and the one or more control wells at at least three time points after adding the one or more test compounds; and analyzing impedance measurements from the one or more test compound wells and the one or more control wells at at least three time points after adding the one, or more test compounds, in which changes in impedance can provide information about cell responses to the one or more test compounds.
  • a test compound can be any compound, including a small molecule, a large molecule, a molecular complex, an organic molecule, an inorganic molecule, a biomolecule such as but not limited to a lipid, a steroid, a carbohydrate, a fatty acid, an amino acid, a peptide, a protein, a nucleic acid, or any combination of these.
  • a test compound can be a synthetic compound, a naturally occurring compound, a derivative of a naturally-occurring compound, etc. The structure of a test compound can be known or unknown.
  • Information about cell responses to the one or more test compounds includes, but is not limited to, information about cell attachment or adhesion status (e.g. the degree of cell spread, the attachment area of a cell, the degree of tightness of cell attachment, cell morphology) on the substrate including on the electrodes, cell growth or proliferation status; number of viable cells and/or dead cells in the well; cytoskeleton change and reorganization and number of cells going through apoptosis and/or necrosis.
  • Information about cell status may also include any compound-cell interaction leading to any change to one or more of above cell status indicators. For example, if the compound binds to a receptor on the cell surface and such binding leads to a change in cell morphology, then the binding of compound to the receptor can be assayed by the monitored cell-substrate impedance.
  • the cells used in the assay can be primary cells isolated from any species or can be cells of cell lines.
  • the cells can be genetically engineered cells (For example, cells from a genetically modified organism, such as for example from a "gene knockout” organism, or cells that have been engineered to over-express an endogenous gene or a transgene, or cells whose normal gene expression has been manipulated by use of antisense molecules or silencing RNA.) hi some embodiments, different cell types are added to different wells and the behavior ofthe different cell types in response to one or more compounds is compared.
  • the cell-based assays that be performed with above methods include, but are not limited to, cell adhesion, apoptosis, cell differentiation, cell proliferation, cell survival, cytotoxicity, cell morphology detection, cell quantification, cell quality control, time- dependent cytotoxicity profiling, IgE-mediated cell activation or stimulation, receptor- ligand binding, viral, bacterial, or environmental toxin mediated cell pathologic changes or cell death, detection or quantification of neutralizing antibodies, specific T-cell mediated cytotoxic effect, and cell-based assay for screening or measuring ligand- receptor binding.
  • impedance is preferably monitored from at least one test compound well at at least one time point before adding said at least one test compound to said at least one test compound well.
  • impedance is monitored at four or more time points, at least one of which is prior to the addition of one or more test compounds.
  • impedance is monitored at regular or inegular time intervals for an assay period of from minutes to days, for example, for a period of between several hours and several days.
  • the cell-subsfrate impedance is monitored at at least one time point prior to addition ofthe test compound, and at regular time intervals thereafter.
  • impedance can be measured at one or more intervals before adding the compound and at a regular 2 hour, 1 hour, 30 min or 15 min time intervals after adding the compound.
  • impedance is measured at three or more time points spaced at regular intervals.
  • a real-time assay means allows one to perform the measurement on cell-substrate impedance with various time resolutions, for example, measurement taking place at a longer time interval such as every hour or every two hours, or at a shorter time interval every minute or a few minutes.
  • Impedance can be monitored at one frequency or at more than one frequency. For example, in some prefened embodiments, impedance is monitored over a range of frequencies for each time point at which impedance is monitored.
  • impedance is monitored at at least one frequency between about 1 Hz and about 100 MHz, more preferably at at least one frequency between about 100 Hz and about 2 MHz. It is preferable to perform replicate test compound assays in which more than one fluid container of cells receives the same compound at the same concentration, hi this case, impedance measurements or values can be averaged for the assayed time points for replicate wells. Preferably, a standard deviation for the averaged values is also calculated.
  • analyzing impedance can comprise plotting cell impedance versus time to obtain at least one test compound impedance curve and at least one control impedance curve.
  • At least one test compound impedance curve and said at least one control impedance curve are compared to identify a time frame, if any, in which a test compound curve differs significantly from a control curve, indicating a time frame of an effect of a test compound on cells.
  • the test compound can be hypothesized to affect one or more of, for example, cell attachment or adhesion, cell growth or proliferation, cytoskeleton organization or function, or apoptosis or cell death.
  • data from impedance monitoring of a well that comprises cells and a test compound is compared with data from impedance monitoring of a well that comprises cells in the absence of a test compound, however, this is not a requirement of the present invention.
  • cell number index Methods of calculating a cell index (cell number index) are disclosed herein as well as in parent application U.S. Patent Application 10/705,447, U.S. Patent Application No. 10/987,732,both herein incorporated by reference for disclosures relating to cell number index and its calculation.
  • the cell index calculated from impedance measurements of wells receiving compound can be compared with the cell index calculated from impedance measurements of confrol wells to assess the effect of a compound on cells.
  • cell index calculated from impedance measurements of wells from one or more time points after the addition of a compound can be compared with the cell index calculated from impedance measurements of wells from one or more time points prior to the addition of a compound to assess the effect of a compound on cells.
  • the cell index can be used as an indicator of cytotoxicity.
  • Cell index values (including normalized cell index values and delta cell index values) from at least three time points from at least one test compound well and at least one control well can be plotted versus time to obtain one or more test compound cell index curve and one or more confrol cell index curves.
  • the one or more test compound cell index curves and the one or more control cell index curves can be compared to identify a time frame, if any, in which a test compound curve differs significantly from a control curve, indicating a time frame of an effect of a test compound on cells.
  • the test compound can be hypothesized to affect one or more of, for example, cell attachment or adhesion, cell growth or proliferation, cytoskeleton organization or function, or apoptosis or cell death.
  • Cell index values at three or more assay time points for one or more test compound wells and one or more control wells can be used to derive cell change index (CCI) values or a second order derivatives of cell index at three or more assay time points.
  • CCI cell change index
  • the calculation of cell change index is provided in Section C ofthe present application.
  • the value of CCI at a give time point can be determined to be either approximately equal to 0.7, much greater than 0.7, greater than zero and less than 0.7, approximately equal to zero, less than zero, or much less than zero.
  • CCI approximately equal to 0.7 indicates log rate growth
  • a CCI much greater than 0.7 indicates faster than log rate growth
  • a CCI greater than zero and less than 0.7 indicates slower than log rate growth
  • a CCI approximately equal to zero indicates no growth (a constant cell index)
  • a CCI less than zero indicates cells are detaching from the substrate
  • a CCI much less than zero indicates cell are detaching rapidly from the substrate.
  • differences in CCI value between control and compound treated wells can indicate a time at which the compound has an effect on cells, as well as providing information on the type of effect the compound has.
  • the CCI can further be used to obtain information on the effect of a test compound by plotting CCI versus time for at least three assay time points to obtain a cell change index curve (CCI curve) for at least one control container or well and at at least one test compound container or well.
  • CCI curve cell change index curve
  • One or more test compound CCI curves can be compared with one or more control CCI curves to obtain information on cell status or behavior in response to said at least one test compound, wherein said cellular status or behavior is at least one of: cell attachment or adhesion status; cell growth or proliferation status; the number of viable cells or dead cells; cytoskeleton change or re-organization; or the number of cells going through apoptosis or necrosis.
  • the present invention also provides methods of comparing the effects of a compound on two or more cell types.
  • the method comprises: providing a device ofthe present invention having two or more electrode anays, each of which is associated with a fluid container ofthe device; attaching the device to an impedance analyzer; introducing cells into two or more fluid containers ofthe device that comprise an electrode array, wherein at least one ofthe two or more fluid containers receives one cell type and at least one other ofthe two or more fluid containers receives a different cell type; adding a test compound to the one or more fluid containers receiving one cell type and adding the test compound to the one or more fluid containers receiving a different cell type to provide at least two test compound fluid containers that comprise cells of different types; providing at least two control fluid containers that do not receive test compound, in which at least one ofthe control fluid containers receives cells ofthe one type and at least one ofthe control fluid containers receives cells ofthe different type; monitoring cell-subsfrate impedance ofthe two or more test compound fluid containers that comprise different cell types and the one or
  • the present invention also provides a method for performing a cell-based assay investigating the effect of one or more test compounds on cells using a cell-subsfrate impedance monitoring system ofthe present invention, where the system includes a multi-well cell-substrate impedance monitoring device, an impedance analyzer, a device station comprising electronic circuitry that engages the device and connects the two or more electrode anays ofthe device to the impedance analyzer, and a software program that controls the device station and can record and analyze data from the impedance analyzer.
  • the method includes: providing a multi-well cell-subsfrate impedance measuring system; introducing cells into two or more wells ofthe device that comprise an electrode array, wherein at least one ofthe two or more wells receives one cell type and at least one other ofthe two or more wells receives a different cell type; adding a test compound to the one or more wells receiving one cell type and adding the test compound to the one or more wells receiving a different cell type to provide at least two test compound wells that comprise cells of different types; providing at least two control wells that do not receive test compound, in which at least one ofthe wells receives cells ofthe one type and at least one ofthe control wells receives cells ofthe different type; monitoring cell-subsfrate impedance ofthe two or more test compound wells that comprise different cell types and the one or more confrol wells at at least three time points after adding the one or more test compounds; and analyzing impedance measurements from the two or more test compound wells comprising different cell types and from the one or more control wells at
  • impedance is preferably momtored from at least two test compound wells comprising different cell types at at least one time point before adding test compound to the at least one two compound wells.
  • impedance is momtored at four or more time points, at least one of which is prior to the addition of one or more test compounds.
  • impedance is monitored at regular or inegular time intervals for an assay period of from minutes to days, for example, for a period of between several hours and several days, hi one embodiment ofthe above cell-based assay, the cell-substrate impedance is monitored at at least one time point prior to addition ofthe test compound, and at regular time intervals thereafter.
  • impedance can be measured at one or more intervals before adding the compound and at a regular 2 hour, 1 hour, 30 min or 15 min time intervals after adding the compound.
  • impedance is measured at three or more time points spaced at regular intervals.
  • a realtime assay means allows one to perform the measurement on cell-subsfrate impedance with various time resolutions, for example, measurement taking place at a longer time interval such as every hour or every two hours, or at a shorter time interval every minute or a few minutes.
  • Impedance can be momtored at one frequency or at more than one frequency.
  • impedance is monitored over a range of frequencies for each time point at which impedance is monitored.
  • impedance is monitored at at least one frequency between about 1 Hz and about 100 MHz, more preferably at at least one frequency between about 100 Hz and about 2 MHz.
  • a test compound can be any compound whose effect on cells can be investigated.
  • a test compound used in assays comparing cell responses can be a compound whose effect on one or more ofthe cell types to be assayed is known, or can be a compound whose effects on any ofthe cell types to be assayed are unknown.
  • cells are introduced into at least three wells ofthe device that each comprise an electrode anay, and at least one well that comprises an elecfrode anay and comprises cells does not receive a test compound.
  • a confrol well that does not receive a test compound can be monitored, and its impedance data can be compared with that of wells that receive a compound to determine the effect ofthe test compounds on cells.
  • the cell types used in the assay can be primary cells isolated from any species or can be cells of cell lines.
  • the different cell types are the same type of cell from different individuals, and thus have different genotypes.
  • One or more ofthe cell types can be genetically engineered (For example, cells from a genetically modified organism, such as for example from a "gene knockout” organism, or cells that have been engineered to overexpress an endogenous gene or a transgene, or cells whose normal gene expression has been manipulated by use of antisense molecules or silencing RNA.)
  • genetically modified cells can be compared with confrol cells, hi another example the cells can be, for example, stem cells from different stages of differentiation or of different genotypes whose response to growth factors is being compared.
  • the cells can be cancer cells where the test compound is tested for its cytotoxic effects.
  • the cells can be primary cancer cells ofthe same type isolated from different individuals, for example, or different cancer cell lines, or cancer cells ofthe same type but of different grades.
  • three or more different cell types are added to different wells and the behavior ofthe three or more different cell types in response to one or more compounds is compared.
  • a variety of assays can be employed, where the effect of a test compound on the behavior of two or more cell types in the assay is under investigation.
  • Such assays include, as nonlimiting examples, cell adhesion assays, apoptosis assays, cell differentiation assays, cell proliferation assays, cell survival assays, cytotoxicity assays, cell morphology detection assays, cell quantification assays, cell quality control assays, time-dependent cytotoxicity profiling assays, IgE-mediated cell activation or stimulation assays, receptor-ligand binding assays, viral, bacterial, or environmental toxin mediated cell pathologic changes or cell death assays, detection or quantification of neutralizing antibodies, specific T-cell mediated cytotoxic effect assays, and cell-based assays for screening or measuring ligand-receptor binding.
  • the assays ofthe present invention is preferable to perform replicate test compound assays in which more than one fluid container of cells ofthe same type receives the same compound at the same concentration.
  • impedance measurements or values can optionally be averaged for the assayed time points for replicate wells.
  • a standard deviation for the averaged values is also calculated.
  • time-dependent responses ofthe first and second types of cells are compared to see how similar or different the responses from the two types of cells are.
  • impedance from a first cell type well is plotted versus time to give a first cell type impedance curve and impedance from a second cell type well is plotted versus time to give a second cell type impedance curve.
  • Cell index (including normalized cell index or delta cell index) from wells comprising cells of different types can also be calculated from impedance data and plotted versus time to give cell index curves.
  • the impedance curves or cell index curves from the different cell types can be compared to determine whether the time frame, magnitude, and duration of a cells response to a compound are similar or different.
  • impedance curves or cell index curves generated from control wells comprising each cell type in the absence of compound are compared with the test compound curves to assess the compound-specific effects on each cell type.
  • the effects ofthe compounds on one or more ofthe two or more cell types can be effects on cell attachment or adhesion, cell growth or proliferation; the number of viable cells or dead cells; cytoskeleton organization or function; or the number of cells going through apoptosis or necrosis in response to a test compound.
  • Assays can be designed to investigate the compound's effects on particular cellular processes or activities.
  • the effect of a compound on at least one ofthe cell types used in the assay may be known.
  • the mechanism of action of a compound on at least one ofthe cell types used in the assay may be known.
  • comparison ofthe compound response of one or more different cell types with the compound response of a cell type whose response to the compound is characterized can give information as to the similarity or difference in response of a different cell type to the compound.
  • time-dependent cytotoxic responses of particular cell types to a compound are compared.
  • Cytotoxicity assays can provide information on the sensitivity of one or more cell type to a compound.
  • Figures 10A and B show the responses of various cell types (listed in Table 1) to olomoucine treatment as monitored using a cell-subsfrate imepdnace monitoring system ofthe presnet invention.
  • the indicated cell lines were seeded onto microtiter devices fabricated with electronic sensor anays shown in Figure 1.
  • the cellular responses were continuously monitored at 15 or 30 or 60 minutes time interval before and after freatment with olomoucine. Comparison among these cell index curves showed that certain similarity does exist. Take the treatment of olomoucine at 100 uM as an example.
  • olomoucine treatment resulted in a near-constant cell index for some length of time (for example: 10, 20 or 30 hrs) a long time.
  • This relates to the fact olomoucine is a cell cycle resting compound and for some time period following compound addition, cells do not divide any more and so cell number does not change but cells remain "live". Thus, for such time period, cell index did not change with time.
  • the "near-constant" cell index curves were also observed for cells treated with roscovitine, which is another compound causing cell cycle anest.
  • the cell index curves shown in Figures 10A and 10B are strikingly different from the cell index curves shown in Figure 9A and 9B, and Figure 11 A and 1 IB, where compounds follow different mechanism of compound action.
  • the CI derived from impedance data from wells comprising different cell types and a test compound can be used to derive cell change index (CCI) values for assay time points.
  • CCI values of particular cell types at assay time points can be compared. Such comparisons can indicate whether different cell types are responding similarly to a compound.
  • CCI can also be plotted versus time, and CCI curves of cells of different types assayed with one or more test compounds can be compared to determine the similarities or differences in cellular responses of different cell types to a test compound.
  • the present invention also provides methods of comparing the effects of two or more different compounds on cells.
  • the method comprises: providing a device ofthe present invention having three or more elecfrode anays, each of which is associated with a fluid container ofthe device; attaching the device to an impedance analyzer; introducing cells into three or more fluid containers ofthe device that comprise an electrode anay; adding at least one test compound to at least one ofthe three or more fluid containers comprising cells and adding at least one different test compound to at least one other ofthe three or more fluid containers comprising cells to provide at least two different test compound fluid containers; providing as a confrol fluid container at least one ofthe three or more fluid containers, in which the control fluid container receives cells but does not receive compound; attaching an impedance analyzer to the device; monitoring cell-substrate impedance ofthe two or more different test compound fluid containers that comprise different compounds and the one or more confrol fluid containers at at least three time points after adding the one or more test compounds; and analyzing impedance measurements from the
  • the present invention provides a method for performing a cell- based assay investigating the effect of two or more test compounds on cells using a cell- subsfrate impedance monitoring system.
  • the method includes: a) providing a cell- subsfrate impedance monitoring system ofthe present invention; b) introducing cells into at least two wells ofthe device that each comprise an electrode anay; c) adding to at least one well ofthe device comprising cells and an electrode anay a first test compound; d) adding to at least one other well ofthe device comprising cells and an electrode anay a second test compound; and e) monitoring cell-subsfrate impedance of at least one well comprising cells and a first compound and at least one well comprising cells and a second compound, in which changes in impedance can provide information about cell responses to the first and second compounds.
  • time-dependent responses of cells to the first compound and the second compound are compared to see how similar or different the responses from the two compounds are.
  • time-dependent cytotoxic responses are compared.
  • the cells and test compound that can be used in the assay can be any as described above for assays testing effects of test compounds.
  • impedance measurements or values can optionally be averaged for the assayed time points for replicate wells. Preferably, a standard deviation for the averaged values is also calculated. Impedance monitoring can be as described above for assays testing effects of test compounds. Preferably impedance is monitored from the at least two different test compound wells and at least one control well at at least one time point before adding said at least one test compound to said at least one test compound well. Preferably, impedance is monitored at four or more time points, at least one of which is prior to the addition of one or more test compounds.
  • impedance is monitored at regular or inegular time intervals for an assay period of from minutes to days, for example, for a period of between several hours and several days, h one embodiment ofthe above cell-based assay, the cell-substrate impedance is monitored at at least one time point prior to addition ofthe test compound, and at regular time intervals thereafter.
  • impedance can be measured at one or more intervals before adding the compound and at a regular 2 hour, 1 hour, 30 min or 15 min time intervals after adding the compound.
  • impedance is measured at three or more time points spaced at regular intervals.
  • a real-time assay means allows one to perform the measurement on cell-subsfrate impedance with various time resolutions, for example, measurement taking place at a longer time interval such as every hour or every two hours, or at a shorter time interval every minute or a few minutes.
  • Impedance can be monitored at one frequency or at more than one frequency. For example, in some prefened embodiments, impedance is monitored over a range of frequencies for each time point at which impedance is monitored. Preferably, impedance is monitored at at least one frequency between about 1 Hz and about 100 MHz, more preferably at at least one frequency between about 100 Hz and about 2 MHz.
  • impedance at three or more assay time points can be plotted versus time.
  • impedance at the same three or more assay time points is also plotted versus time.
  • the impedance curves of different compound wells can be compared with the control impedance curve to determine whether the compounds have a similar or different effect on cells.
  • Cell index (including normalized cell index or delta cell index) from wells comprising cells of different types can also be calculated from impedance data and plotted versus time to give cell index curves.
  • the impedance curves or cell index curves from the different cell types can be compared to determine whether the time frame, magnitude, and duration the response of cells to different compounds are similar or different.
  • impedance curves or cell index curves generated from one or more control wells comprising cells in the absence of compound are compared with the test compound curves to assess the compound-specific effects of each compound.
  • the effects ofthe compounds on cells can be for example, effects on cell attachment or adhesion, cell growth or proliferation; the number of viable cells or dead cells; cytoskeleton organization or function; or the number of cells going through apoptosis or necrosis in response to a test compound.
  • Assays can be designed to investigate the compound's effects on particular cellular processes or activities.
  • the effect on cells of one or more ofthe compounds used in the assay may be known.
  • the mechanism of action of one or more compounds used in the assay may be known.
  • comparison ofthe responses of cells to other test compounds used in the assay with cellular responses to the one or more compounds whose effects are characterized can give information as to the similarity or difference in response of different compounds to a known compound.
  • Information about cell responses to the compound includes, but is not limited to, information about cell attachment or adhesion status (e.g.
  • Information about cell status may also include any compound-cell interaction leading to any change to one or more of above cell status indicators. For example, if the compound binds to a receptor on the cell surface and such binding leads to a change in cell morphology, then the binding of compound to the receptor can be assayed by the monitored cell-substrate impedance.
  • the cell-based assays that be performed with above methods include, but not limited to, cell adhesion, cell apoptosis, cell differentiation, cell proliferation, cell survival, cytotoxicity, cell morphology detection, cell quantification, cell quality confrol, time-dependent cytotoxicity profiling, IgE-mediated cell activation or stimulation, receptor-ligand binding, viral and bacterial toxin mediated cell pathologic changes and cell death, detection and quantification of neutralizing antibodies, specific T-cell mediated cytotoxic effect, cell-based assay for screening and measuring ligand-receptor binding.
  • a plurality of compounds can be assayed with multiple cell types, hi one prefened embodiment of this method, time-dependent cytotoxic responses of different cell types to a set of compounds are compared.
  • the CI derived from impedance data from wells comprising different cell types and a test compound can be used to derive cell change index (CCI) values for assay time points.
  • CCI values of particular cell types at assay time points can be compared. Such comparisons can indicate whether different cell types are responding similarly to a compound.
  • CCI can also be plotted versus time, and CCI curves of cells of different types assayed with one or more test compounds can be compared to detennine the similarities or differences in cellular responses of different cell types to a test compound.
  • the time frame, magnitude, and duration of a difference in response as evidenced by the curves can indicate a difference in efficacy or mechanism of compounds.
  • the impedance differences can reflect differences in, for example, cell attachment or adhesion, cell growth or proliferation; the number of viable cells or dead cells; cytoskeleton organization or function; or the number of cells going through apoptosis or necrosis in response to a test compound.
  • assays can be employed, where the effect of two or more test compound on the behavior cells is under investigation.
  • assays include, as nonlimiting examples, cell adhesion assays, apoptosis assays, cell differentiation assays, cell proliferation assays, cell survival assays, cytotoxicity assays, cell morphology detection assays, cell quantification assays, cell quality control assays, time-dependent cytotoxicity profiling assays, IgE-mediated cell activation or stimulation assays, receptor- ligand binding assays, viral, bacterial, or environmental toxin mediated cell pathologic changes or cell death assays, detection or quantification of neutralizing antibodies, specific T-cell mediated cytotoxic effect assays, and cell-based assays for screening or measuring ligand-receptor binding.
  • time-dependent cytotoxic responses of cells to a set of compounds are compared.
  • Cytotoxicity profiling in which the impedance responses of cells in response to a plurality of potentially cytotoxic compounds are compared, can provide information on the efficacy and mechanism of a test compound. Cytotoxicity profiling can be performed by comparing any combination of impedance plots, kinetic parameters derived from impedance plots, CI plots, CCI values, and CCI plots.
  • analyzing the cytotoxicity response may include derivation ofthe slope of change in the time dependent cytotoxicity response at a given compound concenfration.
  • analyzing real-time cytotoxicity response may include derivation of high-order derivatives ofthe time dependent cytotoxicity response with respect to time at a given compound concentration.
  • a method for testing different concentrations of a test compound on cells comprises: providing a device ofthe present invention having three or more electrode anays, each of which is associated with a fluid container ofthe device; attaching the device to an impedance analyzer; introducing cells into at least two ofthe three or more fluid containers ofthe device that comprise an electrode anay; adding different concentrations of a test compound to the two or more fluid containers ofthe device that comprise cells; providing a control fluid container that comprises cells but does not receive compound; monitoring cell-substrate impedance ofthe two or more different test compound fluid containers that comprise different concentrations of a test compound and ofthe one or more confrol fluid containers at at least three time points after adding a test compound; and analyzing impedance measurements from the two or more different test compound fluid containers and one or more control fluid containers at at least three time points after adding a test compound, in which changes in impedance can
  • the present invention provides a method for performing a cell- based assay investigating the effect of two or more concentrations of a test compound on cells using a cell-subsfrate impedance monitoring system.
  • the method includes: providing a cell-substrate impedance monitoring system ofthe present invention; introducing cells into at least two ofthe three or more wells ofthe device that comprise an electrode anay; adding different concentrations of a test compound to the two or more wells ofthe device that comprise cells; providing a control well that comprises cells but does not receive test compound; monitoring cell-subsfrate impedance ofthe two or more different test compound wells that comprise different concentrations of a test compound and the one or more control wells at at least three time points after adding a test compound; and analyzing impedance measurements from the two or more different test compound wells and the one or more confrol wells at at least three time points after adding a test compound, in which changes in impedance can provide information about cell responses to the test compounds.
  • the cells and test compound that can be used in the assay can be any as described above for assays testing effects of test compounds.
  • Impedance monitoring can be as described above for assays testing effects of test compounds.
  • impedance is monitored from the at least two different test compound wells and at least one control well at at least one time point before adding said at least one test compound to said at least one test compound well.
  • impedance is monitored at four or more time points, at least one of which is prior to the addition of one or more test compounds.
  • impedance is monitored at regular or inegular time intervals for an assay period of from minutes to days, for example, for a period of between several hours and several days.
  • the cell-subsfrate impedance is monitored at at least one time point prior to addition ofthe test compound, and at regular time intervals thereafter.
  • impedance can be measured at one or more intervals before adding the compound and at a regular 2 hour, 1 hour, 30 min or 15 min time intervals after adding the compound.
  • impedance is measured at three or more time points spaced at regular intervals.
  • a real-time assay means allows one to perform the measurement on cell-subsfrate impedance with various time resolutions, for example, measurements taking place at a longer time interval such as every hour or every two hours, or at a shorter time interval every minute or a few minutes.
  • Impedance can be monitored at one frequency or at more than one frequency. For example, in some prefened embodiments, impedance is monitored over a range of frequencies for each time point at which impedance is monitored.
  • impedance is momtored at at least one frequency between about 1 Hz and about 100 MHz, more preferably at at least one frequency between about 100 Hz and about 2 MHz.
  • impedance or, preferably, cell index at three or more assay time points is be plotted versus time.
  • impedance at the same three or more assay time points is also plotted versus time.
  • An impedance curve or cell index curve can give an indication ofthe time frame at which a compound affects cell response. In some prefened embodiments, the cell index can be used as an indicator of cytotoxicity.
  • Figures 9 A and B shows the responses of various cell types (listed in Table 1) to doxorubicin treatment as monitored using a cell-substrate imepdnace monitoring system ofthe presnet invention.
  • the indicated cell lines were seeded onto microtiter devices fabricated with electronic sensor anays shown in Figure 1.
  • the cellular responses were continuously monitored at 15 or 30 or 60 minutes time interval before and after freatment with doxorubicin. Comparison among these cell index curves showed that certain similarity does exist. Take the freatment of doxoorubincin at 3.13 uM as an example. For most of cell types tested, initially after the treatment, cell index increased with time in similar way to the cell index from DMSO control wells.
  • the cell index curves shown in Figure 9 are also strikingly different from the cell index curves in Figure 11, where nM concentration of paclitaxel caused an intial cell index decrease for about 15 hrs (it varies between cell types) and then a cell index increase.
  • nM concentration of paclitaxel caused an intial cell index decrease for about 15 hrs (it varies between cell types) and then a cell index increase.
  • These dynamic changes in cell index curves reflect the fact that these different compounds interacts with the cells differently. Compounds that interact with cells in similar way or following same mechanism would result in a similar cell index response curves.
  • One application of this is to investigate the mechanism of compound action based on the observed cell index curves. If cell index responses follow a certain pattern, then one may be able to deduce the mechanism of compound action. Alternatively, if two compounds showed similar, dynamic cell index response curves, then these two compounds may act on the cells with similar or same mechanism of compound action.
  • Figure IIA and 11B shows the responses of various cell types (listed in Table 1) to paclitaxel treatment as monitored using a cell-subsfrate imepdnace monitoring system ofthe presnet invention.
  • the indicated cell lines were seeded onto microtiter devices fabricated with electronic sensor anays shown in Figure 1.
  • the cellular responses were continuously monitored at 15 or 30 or 60 minutes time interval before and after freatment with paclitaxel. Comparison among these cell index curves showed that certain similarity does exist.
  • cell index curve For one particular cell index curve, after the cell index reached a minimum, it then reversed its decreasing trend and started to increase. Such "going down and then going up" feature in cell index curves was also observed in cell index curves for cells freated with vinblastin or colcemid. Examples of cell index curve for vinblastin- freated cells are shown in Figure 16A and Figure 22. All these compounds - i.e., paclitaxel, vinblastin and colcemid, are so called mitotic poisons and follow similar mechanism of drug action. For example, both vinblastin and paclitaxel act on microtubule dynamics within a cell. hi addition, for a given assay time point, cell index (including normalized cell index or delta cell index), can be plotted versus compound concenfration.
  • Such dose response relationships can be used to derive a time-dependent IC5, IC10, IC20, IC30, IC40, IC50, IC60, IC70, IC80, IC90, or IC95.
  • a time-dependent IC50 is calculated for a compound. Determining a range of time-dependent IC50s for a compound provides information on when the effect ofthe compound on cells is maximal.
  • the CI derived from impedance data from wells comprising different cell types and a test compound can be used to derive cell change index (CCI) values for assay time points.
  • CCI values of particular cell types at assay time points can be compared. Such comparisons can indicate whether different cell types are responding similarly to a compound.
  • CCI can also be plotted versus time, and CCI curves of cells of different types assayed with one or more test compounds can be compared to determine the similarities or differences in cellular responses of different cell types to a test compound.
  • the time frame, magnitude, and duration of a difference in response as evidenced by the curves can indicate a difference in efficacy or mechanism of compounds.
  • the impedance differences can reflect differences in, for example, cell attachment or adhesion, cell growth or proliferation; the number of viable cells or dead cells; cytoskeleton organization or function; or the number of cells going through apoptosis or necrosis in response to a test compound.
  • data from impedance monitoring of wells that comprise different cell types are compared.
  • impedance monitoring is performed for different cell types exposed to multiple dose concentrations of a compound.
  • multiple compounds can be tested with multiple cell types.
  • multiple compounds at multiple concentrations can be tested with multiple cell types.
  • the present invention provides a method for performing real-time cytotoxicity assay of a compound, comprising: a) providing an above described system; b) seeding cells to the wells of multiple- well devices; c) adding the compound to the wells containing cells; d) monitoring cell-substrate impedance before and after adding the compound at a regular or inegular time interval; wherein the time dependent impedance change provides information about time dependent cytotoxicity ofthe compound, hi one embodiment, the cell-subsfrate impedance is monitored at regular time intervals, hi exemplary embodiments, the impedance is measured at a regular 2 hour, 1 hour, 30 min or 15 min time interval before and after adding the compound.
  • the present invention provides a method for analyzing and comparing time-dependent cytotoxic effects of a first compound and a second compound on a cell type, comprising : a) performing a real-time cytotoxicity assay on a cell type with the first compound using the method described above; b) performing a real-time cytotoxicity assay on said cell type with the second compound using the method described above; c) comparing the time-dependent cytotoxic responses ofthe first compomid and the second compound to see how similar or different the responses from the two compounds are.
  • time-dependent cytotoxic responses are determined for the first compound at multiple dose concentrations
  • time-dependent cytotoxic responses are determined for the second compound at multiple dose concentrations.
  • time-dependent cytotoxic responses are determined for both first compound and second compound at multiple dose concentrations.
  • the first compound is a compound with a known mechanism for its cytotoxic effect and the second compound is a compound with an unknown mechanism for its cytotoxic effect. If the time dependent cytotoxic responses from the second compound are similar to that ofthe first one, the second compound may follow a similar mechanism for its cytotoxic effect to the first compound.
  • Various approaches may be used in comparing the cytotoxic responses ofthe compounds.
  • a cell index (or cell number index) can optionally be calculated using the impedance values obtained, hi one embodiment ofthe method described above, time dependent IC50 may be derived for the compounds and comparison between their cytotoxic responses is done by comparing their time dependent IC50 curves based on cell index values. If the IC50 curves follow a similar time-dependent trend, the two compounds may follow a similar mechanism for inducing cytotoxicty effects. In another embodiment ofthe method described, direct comparison of time-dependent cytotoxic responses of two compounds are done where the concentrations for the two compounds may be the same or may be different.
  • Direct comparison between time-dependent cytotoxic responses may be done by analyzing the slope of change in the measured responses (that is equivalent to the first order derivative ofthe response with respect to time) and comparing the time-dependent slopes for the two compounds, hi another approach, the time-dependent cytotoxic responses may be analyzed for their higher order derivatives with respect to time. Comparing such high order derivatives may provide additional information as for the mechanisms of compound-induced cytotoxicity.
  • analyzing real-time cytotoxicity response may include the derivation of time-dependent IC50 values for the compound on the multiple cell types.
  • analyzing real-time cytotoxicity response may include derivation ofthe slope of change in the time dependent cytotoxicity response at a given compound concentration.
  • analyzing real-time cytotoxicity response may include derivation of high-order derivatives ofthe time dependent cytotoxicity response with respect to time at a given compound concentration.
  • the above methods are applied to perform cytotoxicity profiling of multiple compounds on multiple cell types.
  • analyzing real-time cytotoxicity response may include derivation ofthe slope of change in the time dependent cytotoxicity response at a given compound concentration. In yet another embodiment ofthe method, analyzing real-time cytotoxicity response may include derivation of high-order derivatives ofthe time dependent cytotoxicity response with respect to time at a given compound concentration.
  • cell index is calculated using the same method as the Cell Index calculation method (A) as described in Section C ofthe present application.
  • Normalized Cell Index was plotted.
  • the Normalized Cell Index at a given time point is calculated by dividing the Cell Index at the time point by the Cell Index at a reference time point.
  • the Normalized Cell Index is 1 at the reference time point.
  • the cell attachment conditions remain unchanged or exhibit little change over the course of an assay that uses impedance monitoring, then the larger the cell index, the larger the number ofthe cells in the wells.
  • a decrease in cell index suggests that some cells are detaching from the substrate surface or dying under the influence ofthe compound.
  • An increase in cell index suggests that more cells are attaching to the subsfrate surfaces, indicating an increase in overall cell number.
  • igure 5 shows curves that represent the time-dependent cell index for H460 cells treated with different concentrations ofthe anticancer drug paclitaxel.
  • the dynamic response ofthe cells to different doses of paclitaxel was monitored by monitoring cell-substrate impedance in real time every 15 minutes for 50 hours after treatment using a cell-subsfrate impedance monitoring system.
  • the cell-substrate impedance monitoring system calculated the cell index at each time point monitored and plotted the cell index as a function of time.
  • H460 cells exhibited a gradual decrease in cell index after compound addition.
  • the cell index reached a minimum at a time dependent on the compound concentration, between about 15 hours and 20 hours after compound addition. After that point, there was a gradual increase in cell index in these wells.
  • the cell index for compound concentration of 33 nanomolar exhibited a near-constant value for up to about 15 hours after compound addition. After 15 hours following compound addition, the cell index exhibited a gradual increase.
  • Information about cell responses to the compound includes, but is not limited to, information about cell attachment or adhesion status (e.g. the degree of cell spread, the attachment area of a cell, the degree of tightness of cell attachment, cell morphology) on the substrate including on the electrodes, cell growth or proliferation status; number of viable cells and/or dead cells in the well; cytoskeleton change and re-organization and number of cells going through apoptosis and/or necrosis.
  • Information about cell status may also include any compound-cell interaction leading to any change to one or more of above cell status indicators.
  • the binding of compound to the receptor can be assayed by the monitored cell-subsfrate impedance.
  • the cell-based assays include, but not limited to, cell adhesion, cell apoptosis, cell differentiation, cell proliferation, cell survival, cytotoxicity, cell morphology detection, cell quantification, cell quality control, time-dependent cytotoxicity profiling, IgE-mediated cell activation or stimulation, receptor-ligand binding, viral and bacterial toxin mediated cell pathologic changes and cell death, detection and quantification of neutralizing antibodies, specific T-cell mediated cytotoxic effect, cell-based assay for screening and measuring ligand-receptor binding.
  • Figure 6 shows curves that represent the time-dependent cell index for H460 cells treated with anticancer drug AC 101103.
  • H460 cells were introduced into wells of a 16X cell-subsfrate impedance monitoring device. The device was positioned on a device station that was located in an incubator maintaining conditions of 37 degrees C and 5% CO 2 . The cells were cultured and treated at their exponential growth phase with different concentrations of AC 101103. The dynamic response ofthe cells to different doses of AC101103 was monitored by measuring impedance in real time every 30 minutes for about 20 hours after treatment on the cell-subsfrate monitoring system.
  • the time-dependent cell index in Figure 6 is significantly different from those shown in Figure 5.
  • the cell index exhibited a near-constant value for about 5 hrs, about 15 hrs and > 20 hrs respectively.
  • the cell index started to increase after about 5 hrs and about 15 hrs following compound addition.
  • the compound concenfration of 25 microgram/ml there was a gradual, yet slow decrease in the cell index after compound addition.
  • the compound concentration of 50 microgram /ml there was an about 10 hr time period over which the cell index remained near-constant, and after that, the cell index decreased steadily.
  • Figure 7 shows dynamic drug response curves of A549 cells treated with doxorubicin.
  • 10,000 A549 cells were seeded into each well of a 16 X device. The device was positioned on a device station that was located in an incubator maintaining conditions of 37 degrees C and 5% CO . Cell attachment and cell growth were momtored on a cell-subsfrate impedance system in real time before treatment by monitoring impedance at regular intervals.
  • doxorubicin at different concentrations was added to the wells. The same volume ofthe solvent used to dissolve the drug was added to some wells as a control.
  • the time, and drug dose dependent cell response (calculated as cell index) to doxorubicin was recorded in real time on the cell-subsfrate impedance monitoring system as shown in this figure.
  • Example 1 Profiling of dynamic cell responses to anti-cancer drugs using ACEA RT-CES system.
  • Cell Change Index to profile the dynamic cell response ofthe different chemotherapeutic agents across the different cell lines.
  • Cell Change Index was calculated for the dynamic RT-CES responses of different cell lines to different chemotherapeutic agents using the definitions described above.
  • RT-CES RT-CES data to mathematically describe cell changes.
  • CCI value indicates that drugs with similar mechanism of action displays similar patterns.
  • the similarity in the dynamic cell-compound interaction patterns may indicate similarity in mechanism of action, mode of resistance and possibly molecular targets.
  • the RT-CES system can be readily adapted to high throughput dynamic screening and analysis of anti-cancer compounds and the information-intensive approach presented in this study can be applied to profile existing cancer chemotherapeutic agents, screen new compounds and provide insight into the mechanism of action of anti-cancer agents.
  • Table I List of cancer cell lines tested against a number of chemical compounds.
  • Table II List of chemical compounds used in the study of profiling cell dynamic responses to a number of anti-cancer compounds.
  • H460, HepG2 and HT1080 cells were maintained in RPMI media containing 5% FBS and 1% penicillin and streptomycin.
  • NIH3T3 cells were maintained in DMEM media containing 10% FBS and 1% penicillin and streptomycin.
  • Cell Proliferation Assays For each ofthe cell type, the indicated number of cells was seeded per well in 96X microtiter plates (e-plateTM) with incorporated electrode structures in individual wells device in 100 ⁇ L of media. The attachment, spreading and proliferation ofthe cells were continuously monitored every 30 minutes using the RT- CESTM system (a cell-substrate impedance monitoring system. Cell proliferation was monitored for a period of 48-72 hours depending on the experiment. The electronic readout, cell-sensor impedance is displayed as a parameter called Cell Index.
  • MTT Assay Increasing numbers of NIH3T3 cells were seeded in 16X e-plate and monitored by RT-CES to obtain the conesponding Cell Index. The media was immediately aspirated and the cells were then assayed by using the standard MTT assay according to the manufacturer's protocol.
  • A549 cells were seeded at a density of 500,000 cells/well in 60 mm tissue culture dishes. Approximately, 24 hours after seeding, the cells were treated with the indicated final concentration of Olomoucine and 16 hours later the cells were washed with PBS, trypsinized, washed twice with PBS and fixed in 70% methanol and stored at 4°C until the staining step. The cells were stained with propidium iodide and analyzed by FACS using a wavelength of 488nm.
  • H460 human lung cancer cells H460 human lung cancer cells, HI 080 fibrosarcoma cells, HepG2 human hepatosarcoma cells and NIH3T3 mouse fibroblasts were seeded at 2500 and 10,000 cells per well in triplicate in ACEA's 96X e-plateTM.
  • the cells were continuously monitored every 30 minutes using the RT-CES system for the indicated period of time ( Figure 18).
  • each cell type has its own characteristic kinetic trace, based on the number of cells seeded, the overall size and morphology of the cells and the degree to which the cells interact with the sensor surface.
  • the adhesion and spreading kinetics as well as time when the cells enter the log growth phase is characteristic of each of the indicated cell lines and therefore offers an excellent internal confrol and a way to standardize and validate stock cultures during different phases ofthe manufacturing process.
  • Figure 19A shows a plot of Cell number seeded versus the Cell Index obtained and indicates that for this particular cell type the RT-CES system could detect as little as 100 cells and the readout is linear by two orders of magnitude all the way up to 10000 cells.
  • the cells were also assayed by the MTT assay.
  • the IC-50 value of Tamoxifen was determined for different cell lines and compared with MTT assay at 48 hours after Tamoxifen addition. According to Table III, the IC-50 values obtained for Tamoxifen for the different cell lines using the RT-CES system is very consistent with the values obtained by the MTT assay, indicating that the RT-CES system can be used to assess the potency of various drugs against different adherent cell lines.
  • A549 non-small lung cancer cells were seeded in ACEA 96X e-plateTM and continuously monitored until the cells reached the log growth phase at which point different concentrations of paclitaxel were added to the cells at the indicated final concentration.
  • paclitaxel at the highest concentration initially induces a cytotoxic effect which is mainly due to cell death as judged by Annexin V staining ( Figure 20B).
  • the cells recover from the initial cytotoxic effect ofthe drug and start to re-proliferate.
  • RT-CES RT-CES system
  • A549 cells were seeded in ACEA 96X microtiter device and continually monitored by the RT-CES.
  • the cells were treated with either DMSO as the vehicle confrol or with 100 ⁇ M Olomoucine which is a CDK inhibitor and induces cell cycle anest either at G1- S transition or at the G2- M transition, depending on the cell line.
  • a addition of Olomoucine to exponentially growing A549 cells causes the trace ofthe Cell Index recordings ofthe cells to level off and remain in a steady state that is reminiscent of cell cycle block, where the cells are neither proliferating nor dying off.
  • the control cells treated with DMSO continue to proliferate until they reach confluence, at which time they are contact inhibited and the Cell Index recording levels off.
  • A549 cells growing on tissue culture dish were treated with the same concentrations of DMSO and Olomoucine and subjected to flow cytomefry analysis.
  • the flow cytomefry analysis indicates that treatment of A549 cells with the indicated concentration of Olomoucine induces cell cycle anest at the G2- M transition, where CDKs such as CDK2 is active.
  • Figure 22 shows the characteristic trace of A549 cells monitored by RT-CESTM and treated with different concentrations of 5-fluorouracil, vinblastine and staurosporine.
  • dynamic monitoring ofthe interaction ofthe indicated cytotoxic agents leads to the generation of characteristic kinetic patterns that is dependent on the cellular background, the concentration ofthe drug, the duration of exposure and the mechanism of drug action. Since each compound has its own characteristic pattern, these kinetic traces could potentially be used to determine the mechanism of action of compounds with unknown targets by comparing the kinetic profile to the profile of compounds with known mechanism of action.
  • RT-CES system Label-free and dynamic monitoring of cell proliferation, viability and cytotoxicity using the RT-CES system offers very distinct and important advantages over traditional endpoint assays. It allows for built in internal quality confrol to assure consistency and reproducibility between the different assays. Dynamic monitoring allows for observation ofthe entire episode of drug interaction with target cells and the user can therefore have a better understanding ofthe mode and mechanism of drug interaction. Furthermore, the actual kinetic trace ofthe drug interaction with the target cell is very significant because it can offer clues as to the mechanism of drug interaction with the target cell. Finally, since each compound or drug has its own characteristic profile with respect to its interaction with target cells, the RT-CES system can be used as a way to determine the mechanism of action of drugs with unknown targets. Table III.
  • IC-50 values for Tamoxifen freatment of different cancer cell lines using the RT-CES system Comparison of IC-50 values for Tamoxifen freatment of different cancer cell lines using the RT-CES system versus MTT assay.
  • the indicated cell lines were seeded in ACEA 16X devices and monitored by RT-CES. Approximately 24 hours later, the cells were freated with increasing concentrations of Tamoxifen and then continually monitored by RT-CES. The experiment was stopped about 48 hours later and the cells in the 16X devices were assayed by using MTT.
  • the IC-50 values derived from RT-CES system are time-dependent, hi the table, the IC-50 values at about 48 hrs after compound freatment are shown for RT-CES system determination and MTT assay.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Sustainable Development (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des dispositifs, des systèmes et des procédés de dosage de cellules au moyen de la surveillance de l'impédance de substrats cellulaires. Dans un aspect, l'invention concerne des dispositifs de surveillance de l'impédance de substrats cellulaires qui comprennent des réseaux d'électrodes sur un substrat non-conducteur, chacun de ces réseaux présentant une résistance d'électrode approximativement uniforme sur l'ensemble du réseau. Dans un autre aspect, l'invention concerne des systèmes de surveillance de substrats cellulaires comprenant au moins un dispositif de surveillance de substrats cellulaires dotés de puits ayant chacun un réseau d'électrodes, un analyseur d'impédance, un dispositif qui relie les réseaux de puits individuels à l'analyseur d'impédance et un logiciel de commande dudit dispositif et de l'analyseur d'impédance. Dans un autre aspect encore, l'invention concerne des dosages cellulaires qui utilisent la surveillance d'impédance pour détecter des changements au niveau du comportement ou de l'état cellulaire. Les procédés permettent de tester les effets des composés sur les cellules, par exemple dans des dosages de cytotoxicité. L'invention concerne enfin des procédés de profilage de cytotoxicité de composés.
EP05722991A 2004-02-09 2005-02-09 Systemes de detection de cellules electroniques en temps reel et applications en matiere de profilage de cytotoxicite et dosages de composes Withdrawn EP1749203A4 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP11193882.5A EP2450698B1 (fr) 2004-02-09 2005-02-09 Système de détection de cellule électronique en temps réel et application pour le profilage de la cytotoxicité et l'analyse de composés
EP13171137.6A EP2639576B1 (fr) 2004-02-09 2005-02-09 Système de détection de cellule électronique en temps réel et application pour le profilage de la cytotoxicité et l'analyse de composés

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US54292704P 2004-02-09 2004-02-09
US54871304P 2004-02-27 2004-02-27
US61460104P 2004-09-29 2004-09-29
US10/987,732 US7192752B2 (en) 2002-12-20 2004-11-12 Real time electronic cell sensing systems and applications for cell-based assays
PCT/US2005/004481 WO2005077104A2 (fr) 2004-02-09 2005-02-09 Systemes de detection de cellules electroniques en temps reel et applications en matiere de profilage de cytotoxicite et dosages de composes

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP11193882.5A Division EP2450698B1 (fr) 2004-02-09 2005-02-09 Système de détection de cellule électronique en temps réel et application pour le profilage de la cytotoxicité et l'analyse de composés
EP13171137.6A Division EP2639576B1 (fr) 2004-02-09 2005-02-09 Système de détection de cellule électronique en temps réel et application pour le profilage de la cytotoxicité et l'analyse de composés

Publications (2)

Publication Number Publication Date
EP1749203A2 true EP1749203A2 (fr) 2007-02-07
EP1749203A4 EP1749203A4 (fr) 2009-05-06

Family

ID=40518464

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05722991A Withdrawn EP1749203A4 (fr) 2004-02-09 2005-02-09 Systemes de detection de cellules electroniques en temps reel et applications en matiere de profilage de cytotoxicite et dosages de composes

Country Status (4)

Country Link
EP (1) EP1749203A4 (fr)
CN (1) CN101400780B (fr)
CA (1) CA2556219A1 (fr)
WO (1) WO2005077104A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560269B2 (en) 2002-12-20 2009-07-14 Acea Biosciences, Inc. Real time electronic cell sensing system and applications for cytotoxicity profiling and compound assays
US8263375B2 (en) 2002-12-20 2012-09-11 Acea Biosciences Dynamic monitoring of activation of G-protein coupled receptor (GPCR) and receptor tyrosine kinase (RTK) in living cells using real-time microelectronic cell sensing technology
US11346797B2 (en) 2002-12-20 2022-05-31 Agilent Technologies, Inc. System and method for monitoring cardiomyocyte beating, viability, morphology and electrophysiological properties
US10551371B2 (en) 2003-11-10 2020-02-04 Acea Biosciences, Inc. System and method for monitoring cardiomyocyte beating, viability and morphology and for screening for pharmacological agents which may induce cardiotoxicity or modulate cardiomyocyte function
US10215748B2 (en) 2002-12-20 2019-02-26 Acea Biosciences, Inc. Using impedance-based cell response profiling to identify putative inhibitors for oncogene addicted targets or pathways
US9612234B2 (en) 2008-05-05 2017-04-04 Acea Biosciences, Inc. Data analysis of impedance-based cardiomyocyte-beating signals as detected on real-time cell analysis (RTCA) cardio instruments
US10539523B2 (en) 2002-12-20 2020-01-21 Acea Biosciences, Inc. System and method for monitoring cardiomyocyte beating, viability, morphology, and electrophysiological properties
CA2550274A1 (fr) 2003-11-12 2005-05-26 Acea Biosciences, Inc. Systemes de detection de cellules electroniques en temps reel pour des epreuves a base de cellules
WO2006015387A2 (fr) 2004-08-04 2006-02-09 Xiao Xu Procede de dosage de la destruction de cellules cibles par des cellules tueuses naturelles, des lymphocytes t cytotoxiques et des neutrophiles, a l'aide de la technique de detection micro-electronique de cellules en temps reel
ATE477486T1 (de) 2006-01-04 2010-08-15 Novartis Ag Antikörperabhängiger zellulärer zytotoxizitätstest
EP2064644A4 (fr) * 2006-09-20 2010-12-29 Acea Biosciences Inc Utilisation du profilage cytologique base sur l'impedance pour classer des profils de reponses cellulaires lors d'une exposition a des agents biologiquement actifs
EP2103933B1 (fr) 2008-02-25 2011-07-27 Universität Leipzig Dispositif et procédé de mesure d'impédance dans des tissus organotypiques
WO2009137440A1 (fr) 2008-05-05 2009-11-12 Acea Biosciences, Inc. Surveillance sans marqueur d’un couplage excitation-contraction et cellules pouvant être excitées utilisant des systèmes fondés sur l'impédance avec une résolution dans le temps de l'ordre de la milliseconde
US8771202B2 (en) 2010-01-19 2014-07-08 Becton Dickinson And Company Electrode layout for blood test sensor strip
CN103675031B (zh) * 2013-12-18 2015-09-02 江苏大学 一种高通量细胞毒性检测方法
EP3035052A1 (fr) 2014-12-18 2016-06-22 Helmholtz-Zentrum für Infektionsforschung GmbH Procédé et dispositif de mesure pour la détermination de la vitesse de croissance d'un biofilm
US12066428B2 (en) 2015-11-20 2024-08-20 Agilent Technologies, Inc. Cell-substrate impedance monitoring of cancer cells
EP3377607A4 (fr) * 2015-11-20 2019-12-11 ACEA Biosciences Inc. Surveillance de l'impédance de substrat cellulaire de cellules cancéreuses
US11746328B2 (en) 2017-03-03 2023-09-05 Agilent Technologies, Inc. Methods and systems for functional maturation of iPSC and ESC derived cardiomyocytes
CN111492239A (zh) * 2017-08-01 2020-08-04 安捷伦科技有限公司 不同谱系、起源或分期的癌细胞的细胞-基质阻抗监测
RO133794A2 (ro) * 2018-06-13 2019-12-30 Centrul Internaţional De Biodinamică Metodă şi dispozitiv de detecţie a unor compuşi bioactivi, de ex. citotoxici, utilizând senzori cu celule stimulate
US11733323B2 (en) 2018-06-13 2023-08-22 Centrul International De Biodinamica Systems and methods for measuring cellular response to target analytes by controlled application of an oscillating stimulus
CN111751522B (zh) * 2019-03-27 2023-06-20 中国科学院宁波工业技术研究院慈溪生物医学工程研究所 一种细胞检测分析仪及细胞增殖信息的检测方法
CN110568037B (zh) * 2019-09-02 2021-12-03 江南大学 用于啶虫脒和吡虫啉联合毒性评价的电化学细胞传感器的构建方法及其应用
US20210301245A1 (en) 2020-03-29 2021-09-30 Agilent Technologies, Inc. Systems and methods for electronically and optically monitoring biological samples
CN111735752A (zh) * 2020-07-01 2020-10-02 京东方科技集团股份有限公司 细胞检测装置和细胞检测系统
CN112485301B (zh) * 2020-11-25 2023-07-14 三诺生物传感股份有限公司 一种电化学测试装置的测试方法、系统、设备及介质

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187096A (en) * 1991-08-08 1993-02-16 Rensselaer Polytechnic Institute Cell substrate electrical impedance sensor with multiple electrode array
WO2004010103A2 (fr) * 2002-07-20 2004-01-29 Acea Biosciences, Inc. Dispositifs a base d'impedance et procedes a utiliser dans des dosages
WO2005047482A2 (fr) * 2003-11-12 2005-05-26 Xiao Xu Systemes de detection de cellules electroniques en temps reel pour des epreuves a base de cellules

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3890201A (en) * 1974-09-26 1975-06-17 Bactomatic Inc Multi-chamber impedance measuring module-cap combination
US4067951A (en) * 1975-11-19 1978-01-10 Bactomatic Inc. Process for making impedance measuring module
JPH11187865A (ja) * 1997-12-25 1999-07-13 Matsushita Electric Ind Co Ltd 細胞電位測定電極及びこれを用いた測定装置
US6477479B1 (en) * 1998-12-11 2002-11-05 Symyx Technologies Sensor array for rapid materials characterization
WO2001025769A2 (fr) * 1999-10-01 2001-04-12 Sophion Bioscience A/S Substrat et procede destines a determiner et/ou surveiller des proprietes electrophysiologiques de canaux ioniques
TWI245895B (en) * 2001-11-29 2005-12-21 Sun-Wing Tong Molecular detection and assay by electrobiochip micro-array

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187096A (en) * 1991-08-08 1993-02-16 Rensselaer Polytechnic Institute Cell substrate electrical impedance sensor with multiple electrode array
WO2004010103A2 (fr) * 2002-07-20 2004-01-29 Acea Biosciences, Inc. Dispositifs a base d'impedance et procedes a utiliser dans des dosages
WO2005047482A2 (fr) * 2003-11-12 2005-05-26 Xiao Xu Systemes de detection de cellules electroniques en temps reel pour des epreuves a base de cellules

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EHRET R ET AL: "Monitoring of cellular behaviour by impedance measurements on interdigitated electrode structures" BIOSENSORS & BIOELECTRONICS, ELSEVIER SCIENCE PUBLISHERS, BARKING, GB, vol. 12, no. 1, 1 January 1997 (1997-01-01), pages 29-41, XP002272321 ISSN: 0956-5663 *
See also references of WO2005077104A2 *
WOLF B ET AL: "Monitoring of cellular signalling and metabolism with modular sensor-technique: the PhysioControl-Microsystem (PCM)" BIOSENSORS & BIOELECTRONICS, ELSEVIER SCIENCE PUBLISHERS, BARKING, GB, vol. 13, no. 5, 15 March 1998 (1998-03-15), pages 501-509, XP002408458 ISSN: 0956-5663 *
XIAO C ET AL: "An In-Depth Analysis of Electric Cell-Substrate Impedance Sensing to Study the Attachment and Spreading of Mammalian Cells" ANALYTICAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. COLUMBUS, US, vol. 74, no. 6, 15 March 2002 (2002-03-15), pages 1333-1339, XP002977290 ISSN: 0003-2700 *

Also Published As

Publication number Publication date
WO2005077104A2 (fr) 2005-08-25
CA2556219A1 (fr) 2005-08-25
CN101400780B (zh) 2012-06-20
WO2005077104A3 (fr) 2008-08-14
EP1749203A4 (fr) 2009-05-06
CN101400780A (zh) 2009-04-01

Similar Documents

Publication Publication Date Title
US9399787B2 (en) Real-time electronic cell sensing system and applications for cytotoxicity profiling and compound assays
WO2005077104A2 (fr) Systemes de detection de cellules electroniques en temps reel et applications en matiere de profilage de cytotoxicite et dosages de composes
US11604197B2 (en) Real time electronic cell sensing systems and applications for cell-based assays
US7468255B2 (en) Method for assaying for natural killer, cytotoxic T-lymphocyte and neutrophil-mediated killing of target cells using real-time microelectronic cell sensing technology
US10168318B2 (en) Method of measuring cell-substrate impedance in living cells to identify compounds affecting receptor tyrosine kinase (RTK) activity and pathways
US7732127B2 (en) Dynamic monitoring of cell adhesion and spreading using the RT-CES system
EP1773979B1 (fr) Controle dynamique de l'activation de la proteine g (gpcr) dans des cellules vivantes mettant en oeuvre la technologie de detection micro-electronique de cellules en temps reel
EP2639576B1 (fr) Système de détection de cellule électronique en temps réel et application pour le profilage de la cytotoxicité et l'analyse de composés
US20230145666A1 (en) Real time electronic cell sensing systems and applications for cell-based assays
EP1800312A2 (fr) Surveillance dynamique de l'adhesion et de la diffusion cellulaire a l'aide du systeme rt-ces

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060906

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

DAX Request for extension of the european patent (deleted)
PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

A4 Supplementary search report drawn up and despatched

Effective date: 20090403

17Q First examination report despatched

Effective date: 20110608

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20111220